Biotech Industry Financials, Performance and Ratios
-
Industry Score
43.7 /100
Rank 77 out of 131 Industries -
Advance/Decline
193/92
-
No. of Companies285
-
Avg. Market Cap2,664
-
Price to Earning Ratio4.53
-
Price to Earning Growth Ratio0.35
-
Price to Book Ratio13.38
-
Return on Equity35.86
-
Return on Capital Employed-
-
Return on Assets4.63
-
Dividend yield 1 year %0.30 %
-
Net Profit Growth Annual YoY %-30.74 %
-
Net Profit Growth Qtr YoY %-44.65 %
-
Net Profit Growth Qtr QoQ %80.33 %
Show more
*All values are market cap weighted averages.
*All Financial parameters are in Million USD.
Biotech Industry Market Breadth
- < -5%
- -2 to -5%
- 0 to -2%
- 0 to 2%
- 2 to 5%
- > 5%
Biotech Peer comparison
Compare all stocks in Biotech industry listed on stock exchanges
| Stock Name | 3M Price Chart | Market Cap | LTPLast Traded Price | Day High Low (%) | Week High Low (%) | Month High Low (%) | Qtr High Low(%) | 1 Year High low(%) | 3 Year High low(%) | 5 Year High low(%) | 10 Year High low(%) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Elanco Animal Health Inc |
|
12,207.9
|
24.6
|
L
 0.5%
H
24.3
24.8
|
L
 3.2%
H
22.4
24.8
|
L
 15.4%
H
21.4
24.8
|
L
 22.6%
H
19.6
24.8
|
L
 110%
H
8.0
24.8
|
L
 87.8%
H
7.9
24.8
|
L
 -21.5%
H
7.9
37.5
|
L
H
7.9
37.6
|
| Nuvation Bio Inc (Class A) |
|
2,207.8
|
6.4
|
L
 -1.7%
H
6.2
6.6
|
L
 -24.2%
H
6.1
9.1
|
L
 -23.6%
H
6.1
9.8
|
L
 75%
H
3.4
9.8
|
L
 141.2%
H
1.5
9.8
|
L
 165.0%
H
1.0
9.8
|
L
 -40.9%
H
1.0
15.2
|
L
H
1.0
15.2
|
| Arcus Biosciences Inc |
|
2,980.6
|
24.1
|
L
 5.9%
H
22.5
24.5
|
L
 11.1%
H
20.6
24.5
|
L
 11.9%
H
20.6
24.5
|
L
 44.8%
H
15.4
26.4
|
L
 72.9%
H
6.5
26.4
|
L
 18.2%
H
6.5
26.4
|
L
 -32.5%
H
6.5
49.1
|
L
H
6.3
49.1
|
| Whitehawk Therapeutics Inc |
|
137.1
|
2.9
|
L
 5.8%
H
2.7
2.9
|
L
 15.5%
H
2.5
2.9
|
L
 25.4%
H
2.3
2.9
|
L
 42.7%
H
1.9
3.8
|
L
 -3.6%
H
1.4
3.8
|
L
 -77.5%
H
1.2
13.5
|
L
 -83.6%
H
1.2
49.8
|
L
H
1.2
101.3
|
| AbCellera Biologics Inc |
|
1,269.2
|
4.2
|
L
 -0.7%
H
4.1
4.4
|
L
 8.7%
H
3.9
4.7
|
L
 17.1%
H
3.3
4.7
|
L
 -25.2%
H
3.3
6.2
|
L
 41.3%
H
1.9
6.5
|
L
 -59.2%
H
1.9
11.4
|
L
 -90.3%
H
1.9
55.2
|
L
H
1.9
71.9
|
| Arcellx Inc |
|
3,969.5
|
68.7
|
L
 2.9%
H
65.1
69.7
|
L
 10.6%
H
62.2
69.7
|
L
 -4.5%
H
60.4
72.9
|
L
 -20.4%
H
60.4
94.1
|
L
 1.9%
H
47.9
94.1
|
L
 113.5%
H
26.3
107.4
|
L
H
6.0
107.4
|
L
H
6.0
107.4
|
| Adma Biologics Inc |
|
4,288.7
|
18.0
|
L
 1.8%
H
17.5
18.2
|
L
 -1.7%
H
16.2
19.0
|
L
 -8.9%
H
16.2
20.0
|
L
 23.9%
H
13.8
20.5
|
L
 9.3%
H
13.5
25.7
|
L
 430%
H
2.9
25.7
|
L
 774.8%
H
1.0
25.7
|
L
 182.9%
H
1.0
25.7
|
| Adaptive biotech Corp |
|
2,720.5
|
17.8
|
L
 -1.4%
H
17.6
18.1
|
L
 10.6%
H
15.5
18.5
|
L
 15.4%
H
15.3
18.5
|
L
 15.0%
H
13.3
20.8
|
L
 175.9%
H
6.0
20.8
|
L
 79.3%
H
2.3
20.8
|
L
 -71.9%
H
2.3
71.3
|
L
H
2.3
71.3
|
| Aditxt Inc |
|
1.3
|
0.7
|
L
 -4%
H
0.7
0.7
|
L
 -18.2%
H
0.7
0.9
|
L
 -67.9%
H
0.7
2.2
|
L
 -98.7%
H
0.7
64.3
|
L
 -100.0%
H
0.7
438581.3
|
L
 -100.0%
H
0.7
3453280000
|
L
 -100.0%
H
0.7
10000000000
|
L
H
0.7
10000000000
|
| Agenus Inc |
|
158.8
|
4.7
|
L
 1.3%
H
4.6
4.9
|
L
 34.6%
H
3.5
4.9
|
L
 23.2%
H
3.0
4.9
|
L
 15.3%
H
3.0
4.9
|
L
 47.8%
H
1.4
7.3
|
L
 -91.9%
H
1.4
196
|
L
 -92.5%
H
1.4
196
|
L
 -92.7%
H
1.4
196
|
| Aeglea BioTherapeutics Inc |
|
127.7
|
31.5
|
L
 -3.9%
H
31.0
33.7
|
L
 4.0%
H
29.6
33.7
|
L
 -6.2%
H
28
35.0
|
L
 66.7%
H
18.7
35.3
|
L
 107.7%
H
13.9
35.3
|
L
 138.0%
H
2.7
35.3
|
L
 -84.1%
H
2.7
219.8
|
L
H
2.7
318.8
|
| Avalon GloboCare Corp |
|
4.8
|
1.1
|
L
 2.7%
H
1.0
1.1
|
L
 -8.1%
H
1.0
1.3
|
L
 -14.9%
H
0.9
1.4
|
L
 -50.2%
H
0.9
2.4
|
L
 -64.9%
H
0.9
11.7
|
L
 -63.1%
H
0.2
11.7
|
L
 -90.3%
H
0.2
16.5
|
L
H
0.2
135
|
| Aldeyra Therapeutics Inc |
|
254.5
|
4.2
|
L
 2.2%
H
4.1
4.3
|
L
 4.2%
H
3.9
4.3
|
L
 -6.8%
H
3.9
5.7
|
L
 -19.4%
H
3.9
5.8
|
L
 -11.3%
H
1.1
7.2
|
L
 -34.4%
H
1.1
12.0
|
L
 -58.4%
H
1.1
16.0
|
L
 -35.4%
H
1.1
16.7
|
| Alector Inc |
|
205.2
|
1.9
|
L
 -2.1%
H
1.8
1.9
|
L
 11.2%
H
1.7
1.9
|
L
 26.2%
H
1.3
1.9
|
L
 -38.2%
H
1.1
3.4
|
L
 5.0%
H
0.9
3.4
|
L
 -78.4%
H
0.9
9.9
|
L
 -87.7%
H
0.9
43.3
|
L
H
0.9
43.3
|
| Allogene Therapeutics Inc |
|
379.8
|
1.7
|
L
 3.1%
H
1.6
1.7
|
L
 19.9%
H
1.4
1.9
|
L
 11.9%
H
1.3
1.9
|
L
 33.1%
H
1.0
1.9
|
L
 -13.3%
H
0.9
3.8
|
L
 -76.1%
H
0.9
8.4
|
L
 -93.8%
H
0.9
39.1
|
L
H
0.9
55
|
| Altimmune Inc |
|
432.0
|
4.1
|
L
 3.2%
H
4.0
4.2
|
L
 4.6%
H
4.0
4.4
|
L
 -21.4%
H
3.5
5.5
|
L
 3.5%
H
3.5
6.0
|
L
 -38.9%
H
2.9
7.7
|
L
 -74.6%
H
2.1
16.4
|
L
 -69.8%
H
2.1
24.6
|
L
 -99.2%
H
1.5
1050
|
| Alvotech |
|
1,542.4
|
5.0
|
L
 2.5%
H
4.8
5.0
|
L
 8.1%
H
4.6
5.0
|
L
 -11.1%
H
4.4
5.6
|
L
 -37.9%
H
4.3
9.0
|
L
 -62.6%
H
4.3
13.5
|
L
 -60.7%
H
4.3
18
|
L
H
4.3
18
|
L
H
4.3
18
|
| Kalaris Therapeutics Inc |
|
170.8
|
9.1
|
L
 -1.2%
H
8.7
9.4
|
L
 10.5%
H
8.3
10.2
|
L
 2.9%
H
7.9
11.9
|
L
 91.8%
H
4.3
11.9
|
L
 -3.2%
H
0.4
12.9
|
L
 55.8%
H
0.4
12.9
|
L
 -78.3%
H
0.4
47
|
L
H
0.4
49.0
|
| Amgen |
|
176,266.3
|
327.3
|
L
 0.9%
H
323.6
327.8
|
L
 -0.9%
H
319.8
343.1
|
L
 3.0%
H
318.2
343.1
|
L
 12.0%
H
288
346.4
|
L
 21.2%
H
261.4
346.4
|
L
 20.5%
H
211.7
346.9
|
L
 37.7%
H
198.6
346.9
|
L
 125.0%
H
133.6
346.9
|
| AnaptysBio Inc |
|
1,373.1
|
49.6
|
L
 3.1%
H
46.7
50
|
L
 12.9%
H
42.5
50
|
L
 10.4%
H
42
52.5
|
L
 52.8%
H
30.3
52.5
|
L
 239.2%
H
12.2
52.5
|
L
 88.0%
H
12.2
52.5
|
L
 107.7%
H
12.2
52.5
|
L
H
10
134
|
| ANI Pharma Inc |
|
1,897.3
|
84.5
|
L
 2.7%
H
81.6
85.0
|
L
 9.0%
H
75.1
87
|
L
 5.1%
H
75.1
87
|
L
 -4.7%
H
75.1
97
|
L
 56.7%
H
53.4
99.5
|
L
 92.2%
H
36.5
99.5
|
L
 165.6%
H
22.3
99.5
|
L
 132.2%
H
22.3
99.5
|
| Anixa Biosciences Inc |
|
107.0
|
3.3
|
L
 -0.9%
H
3.2
3.3
|
L
 2.2%
H
3.1
3.6
|
L
 -9.2%
H
3.1
3.6
|
L
 -28.1%
H
3.1
5.5
|
L
 48.4%
H
2.1
5.5
|
L
 -35%
H
2.1
6.5
|
L
 -16.0%
H
2.1
8.1
|
L
 8.7%
H
0.6
8.1
|
| AN2 Therapeutics Inc |
|
35.6
|
1.3
|
L
 3.2%
H
1.2
1.4
|
L
 21.5%
H
1.1
1.4
|
L
 8.3%
H
1
1.4
|
L
 3.2%
H
1
1.4
|
L
 3.2%
H
1
1.6
|
L
 -87.8%
H
0.9
22.2
|
L
H
0.9
23.6
|
L
H
0.9
23.6
|
| Applied Dna Sciences Inc |
|
7.0
|
1.6
|
L
 3.9%
H
1.5
1.7
|
L
 6.7%
H
1.5
1.7
|
L
 -36.5%
H
1.2
2.7
|
L
 -58.2%
H
1.2
6.2
|
L
 -98.9%
H
0.7
157.5
|
L
 -100.0%
H
0.7
28335
|
L
 -100.0%
H
0.7
204600
|
L
 -100.0%
H
0.7
2244000
|
| Aptevo Therapeutics Inc |
|
9.0
|
9.1
|
L
 1.9%
H
8.5
9.1
|
L
 13.8%
H
7.7
9.9
|
L
 -55.5%
H
7.7
20.0
|
L
 -68.6%
H
7.7
30.1
|
L
 -99.5%
H
7.7
1807.2
|
L
 -100.0%
H
7.7
1512086.4
|
L
 -100.0%
H
7.7
25324516.8
|
L
H
7.7
68020444.8
|
| AquaBounty Tech Inc |
|
4.1
|
1.1
|
L
 1.9%
H
1.0
1.1
|
L
 20.2%
H
0.9
1.1
|
L
 15.1%
H
0.8
1.1
|
L
 -38.9%
H
0.8
2.0
|
L
 48.6%
H
0.5
3.0
|
L
 -94.4%
H
0.5
23.6
|
L
 -99.5%
H
0.5
266.4
|
L
H
0.5
610
|
| Arvinas Inc |
|
812.4
|
12.7
|
L
 2.9%
H
12.0
12.8
|
L
 6.9%
H
11.8
12.8
|
L
 0.6%
H
11
12.8
|
L
 29.1%
H
8.8
14.2
|
L
 -29.8%
H
5.9
20.4
|
L
 -62.2%
H
5.9
53.1
|
L
 -84.6%
H
5.9
108.5
|
L
H
5.9
108.5
|
| Arrowhead Pharma Inc |
|
9,061.6
|
65
|
L
 -0.8%
H
64.7
66.0
|
L
 -8.2%
H
63
69.4
|
L
 -7.3%
H
59.5
76.8
|
L
 79.3%
H
34.6
76.8
|
L
 243.7%
H
9.6
76.8
|
L
 76.5%
H
9.6
76.8
|
L
 -19.8%
H
9.6
93.7
|
L
 1297.8%
H
1.2
93.7
|
| LeonaBio Inc |
|
25.2
|
6.4
|
L
 -2.1%
H
6.4
6.6
|
L
 -7.9%
H
6.4
7.5
|
L
 65.4%
H
3.8
8.4
|
L
 71.1%
H
3.6
8.4
|
L
 20.5%
H
2.2
8.4
|
L
 -83.4%
H
2.2
44.1
|
L
 -97.7%
H
2.2
285
|
L
H
2.2
347.9
|
| Aurinia Pharma Inc |
|
1,997.4
|
15.2
|
L
 1.1%
H
14.8
15.2
|
L
 -1.9%
H
14.8
16.2
|
L
 -4.4%
H
14.8
16.5
|
L
 36.5%
H
10.9
16.5
|
L
 97.8%
H
6.6
16.5
|
L
 66.3%
H
4.7
16.5
|
L
 9.1%
H
4.1
34.0
|
L
 618.0%
H
1.4
34.0
|
| Aura Biosciences Inc |
|
332.1
|
5.2
|
L
 3.4%
H
5.0
5.3
|
L
 1.4%
H
4.8
5.5
|
L
 -20.0%
H
4.8
6.6
|
L
 -14.7%
H
4.8
6.7
|
L
 -30.3%
H
4.3
8.3
|
L
 -54.1%
H
4.3
13.5
|
L
H
4.3
26.2
|
L
H
4.3
26.2
|
| Tectonic Therapeutic Inc |
|
371.9
|
19.9
|
L
 0.6%
H
19.5
20.1
|
L
 -3.5%
H
19
21.9
|
L
 0.6%
H
17.8
22
|
L
 23.5%
H
15.5
26
|
L
 -47.5%
H
13.7
61.1
|
L
 84.0%
H
1.4
61.1
|
L
 -88.4%
H
1.4
240.8
|
L
H
1.4
644.4
|
| Jade Biosciences Inc |
|
707.7
|
14.4
|
L
 4.0%
H
13.1
14.7
|
L
 9.0%
H
12.5
14.7
|
L
 -4.2%
H
12.5
17.7
|
L
 57.9%
H
8.4
17.7
|
L
 -83.6%
H
6.6
100.1
|
L
 -98.4%
H
6.6
1134.5
|
L
H
6.6
1134.5
|
L
H
6.6
1134.5
|
| Anavex Life Sciences Corp |
|
436.9
|
4.9
|
L
 5.4%
H
4.7
4.9
|
L
 22.0%
H
4.0
4.9
|
L
 21.6%
H
3.5
4.9
|
L
 -43.3%
H
2.9
9.5
|
L
 -53.7%
H
2.9
14.0
|
L
 -53.8%
H
2.9
14.4
|
L
 -13.1%
H
2.9
31.5
|
L
 33.2%
H
1.3
31.5
|
| Axsome Therapeutics Inc |
|
8,914.5
|
176.8
|
L
 1.4%
H
172.7
177.8
|
L
 2.9%
H
165.8
179.5
|
L
 19.3%
H
145.1
184.4
|
L
 46.0%
H
120.1
184.4
|
L
 98.1%
H
84.5
184.4
|
L
 162.7%
H
53.7
184.4
|
L
 122.4%
H
19.4
184.4
|
L
 1630.2%
H
1.9
184.4
|
| Aziyo Biologics Inc (Class A) |
|
-
|
0.9
|
L
 27.5%
H
0.7
0.9
|
L
 39.7%
H
0.6
0.9
|
L
 25.7%
H
0.5
0.9
|
L
 -2.2%
H
0.5
1.0
|
L
 -48.8%
H
0.5
2.6
|
L
 -77.5%
H
0.5
5.4
|
L
 -93.9%
H
0.5
18.2
|
L
H
0.5
18.2
|
| Akari Therapeutics PLC (ADR) |
|
9.6
|
0.3
|
L
 -3.6%
H
0.3
0.3
|
L
 -6.9%
H
0.3
0.3
|
L
 -30.8%
H
0.2
0.4
|
L
 -71.3%
H
0.2
1.0
|
L
 -77.7%
H
0.2
1.7
|
L
 -97.5%
H
0.2
10.8
|
L
 -99.4%
H
0.2
84.2
|
L
 -99.9%
H
0.2
444
|
| Autolus Therapeutics PLC (ADR) |
|
377.9
|
1.4
|
L
 3.7%
H
1.3
1.4
|
L
 -29%
H
1.3
2.1
|
L
 -11.8%
H
1.3
2.1
|
L
 -13.9%
H
1.2
2.1
|
L
 -38.3%
H
1.1
2.7
|
L
 -32.4%
H
1.1
7.5
|
L
 -83.9%
H
1.1
9.4
|
L
H
1.1
53.2
|
| BridgeBio Pharma Inc |
|
15,025.5
|
78.0
|
L
 -1.4%
H
76.8
79.3
|
L
 5.4%
H
71.0
79.9
|
L
 3.8%
H
71.0
79.9
|
L
 39.3%
H
52.8
79.9
|
L
 131.2%
H
28.3
79.9
|
L
 791.1%
H
7.9
79.9
|
L
 18.7%
H
5.0
79.9
|
L
H
5.0
79.9
|
| BioAtla Inc |
|
20.6
|
0.4
|
L
 12.9%
H
0.3
0.4
|
L
 -18.6%
H
0.3
0.5
|
L
 -57.3%
H
0.3
0.9
|
L
 -61.5%
H
0.3
1.4
|
L
 -30%
H
0.2
1.4
|
L
 -89.9%
H
0.2
4.4
|
L
 -99.2%
H
0.2
76.6
|
L
H
0.2
76.6
|
| BioCardia Inc |
|
15.1
|
1.4
|
L
 2.2%
H
1.4
1.4
|
L
 11.8%
H
1.3
1.4
|
L
 -2.1%
H
1.2
1.5
|
L
 -6.0%
H
1.2
1.6
|
L
 -36.9%
H
1
3.2
|
L
 -95.9%
H
1
43.8
|
L
 -97.4%
H
1
82.2
|
L
 -98.8%
H
1
2073.6
|
| Biocryst Pharma Inc |
|
1,420.4
|
6.7
|
L
 -0.2%
H
6.7
6.9
|
L
 -11.1%
H
6.7
8.1
|
L
 -11.0%
H
6.7
8.1
|
L
 -4.3%
H
6
8.2
|
L
 -15.0%
H
6
11.3
|
L
 -33.7%
H
4.0
11.3
|
L
 -17.3%
H
4.0
20.0
|
L
 -9.2%
H
1.4
20.0
|
| BriaCell Therapeutics Corp |
|
9.1
|
4.8
|
L
 -55.8%
H
4.8
5.2
|
L
 -32.6%
H
4.8
12.1
|
L
 -49.4%
H
4.8
12.1
|
L
 -57.2%
H
4.8
14.7
|
L
 -99.2%
H
4.8
982
|
L
 -100.0%
H
4.8
12033
|
L
 -99.9%
H
4.8
18526.5
|
L
 -100.0%
H
4.8
138373.2
|
| Black Diamond Therapeutics Inc |
|
159.0
|
2.8
|
L
 1.5%
H
2.7
2.8
|
L
 7.3%
H
2.6
2.9
|
L
H
2.4
2.9
|
L
 -26.6%
H
2.2
4.9
|
L
 20.8%
H
1.2
4.9
|
L
 5.7%
H
1.2
7.7
|
L
 -90.6%
H
1.2
30.7
|
L
H
1.2
46.3
|
| Beam Therapeutics Inc |
|
3,559.7
|
35.1
|
L
 1.5%
H
34.3
36.2
|
L
 23.8%
H
27.3
36.4
|
L
 28.2%
H
25.5
36.4
|
L
 38.2%
H
20.2
36.4
|
L
 37.4%
H
13.5
36.4
|
L
 -18.9%
H
13.5
50.7
|
L
 -64.2%
H
13.5
138.5
|
L
H
13
138.5
|
| Biogen |
|
24,943.8
|
170.0
|
L
 -4.6%
H
165.6
178.4
|
L
 -6.9%
H
165.6
190.2
|
L
 -2.3%
H
165.6
190.2
|
L
 17.5%
H
138
190.2
|
L
 13.2%
H
110.0
190.2
|
L
 -41.0%
H
110.0
319.8
|
L
 -36.2%
H
110.0
468.6
|
L
 -30.9%
H
110.0
468.6
|
| BioVie Inc |
|
9.3
|
1.2
|
L
 -2.4%
H
1.2
1.3
|
L
 -10.8%
H
1.2
1.4
|
L
 -14.5%
H
1.1
1.5
|
L
 -36.4%
H
1.1
2.1
|
L
 -94.1%
H
1.1
22.9
|
L
 -99.8%
H
1.1
1139
|
L
 -100.0%
H
1.1
4609.8
|
L
 -99.9%
H
1.1
5625
|
| Biomarin pharma Inc - Registered Shares |
|
10,756.5
|
56.0
|
L
 1.4%
H
55.2
56.3
|
L
 -6.8%
H
54.4
61.9
|
L
 5.0%
H
50.9
63.9
|
L
 6.8%
H
50.8
63.9
|
L
 -16.4%
H
50.8
73.5
|
L
 -50.3%
H
50.8
117.8
|
L
 -31.7%
H
50.8
117.8
|
L
 -33.4%
H
50.8
131.9
|
| Bionano Genomics Inc |
|
15.6
|
1.5
|
L
 -3.2%
H
1.5
1.6
|
L
 -5.0%
H
1.5
1.6
|
L
 -5.6%
H
1.5
1.7
|
L
 -21.9%
H
1.5
2.2
|
L
 595.5%
H
0.1
11.6
|
L
 -91.5%
H
0.1
20.2
|
L
 -97.3%
H
0.1
156.9
|
L
H
0.1
156.9
|
| Benitec Biopharma Inc |
|
412.8
|
12.2
|
L
 -0.9%
H
12.0
12.4
|
L
 1.7%
H
11.4
12.7
|
L
 1.8%
H
9.9
14.4
|
L
 -18.7%
H
9.9
16.8
|
L
 17.3%
H
9.7
17.2
|
L
 209.4%
H
1.9
17.2
|
L
 -80.4%
H
1.9
178.3
|
L
 -98.8%
H
1.9
1371.3
|
| Bon Natural Life Ltd |
|
14.0
|
1.7
|
L
H
1.7
1.8
|
L
 1.8%
H
1.6
1.8
|
L
 -5.0%
H
1.5
1.9
|
L
 -19.6%
H
1.5
2.3
|
L
 -95.9%
H
1.1
73.8
|
L
 -99.5%
H
1.1
645
|
L
 -100.0%
H
1.1
4400
|
L
 -100.0%
H
1.1
22532.5
|
| BioXcel Therapeutics Inc |
|
43.7
|
2
|
L
 -2.4%
H
1.9
2.1
|
L
 14.9%
H
1.8
2.1
|
L
 -0.5%
H
1.5
2.1
|
L
 -23.4%
H
1.5
2.8
|
L
 426.3%
H
0.2
8.1
|
L
 -93.1%
H
0.2
34.1
|
L
 -96.1%
H
0.2
67.7
|
L
H
0.2
71.5
|
| Bicycle Therapeutics PLC (ADR) |
|
455.7
|
6.6
|
L
 1.2%
H
6.4
6.6
|
L
H
6.4
7
|
L
 -11.8%
H
6.3
7.5
|
L
 -19.1%
H
6.0
9.1
|
L
 -56.7%
H
6.0
15.4
|
L
 -76.4%
H
6.0
30.0
|
L
 -66.9%
H
6.0
62.1
|
L
H
6.0
62.1
|
| BioNTech SE (ADR) |
|
27,276.2
|
108.7
|
L
 1.4%
H
107.2
109.3
|
L
 10.8%
H
97.8
109.3
|
L
 14.7%
H
91.1
109.3
|
L
 6.3%
H
91.1
113.4
|
L
 -4.4%
H
81.2
126.8
|
L
 -25.1%
H
76.5
147.7
|
L
 5.9%
H
76.5
464
|
L
H
12.5
464
|
| Cabaletta Bio Inc |
|
203.1
|
2.1
|
L
 -1.9%
H
2.1
2.2
|
L
 3.4%
H
2.1
2.3
|
L
 -10.6%
H
2
2.5
|
L
 -15.3%
H
2
3.7
|
L
 -2.3%
H
1.0
3.7
|
L
 -78.9%
H
1.0
26.4
|
L
 -84.7%
H
0.6
26.4
|
L
H
0.6
26.4
|
| CalciMedica Inc |
|
80.5
|
5.6
|
L
 0.7%
H
5.3
5.7
|
L
 -2.1%
H
5.1
6.2
|
L
 29.1%
H
4.2
7.2
|
L
 71.5%
H
3.0
7.2
|
L
 92.8%
H
1.4
7.2
|
L
 -43.0%
H
1
10.6
|
L
 -98.6%
H
1
492.5
|
L
H
1
530.3
|
| Tvardi Therapeutics Inc |
|
44.2
|
4.7
|
L
 3.3%
H
4.4
4.8
|
L
 19.9%
H
3.9
4.8
|
L
 6.8%
H
3.8
4.8
|
L
 -29.6%
H
3.7
7.2
|
L
 -66.3%
H
3.7
43.7
|
L
 -98.8%
H
3.7
449.6
|
L
 -99.3%
H
3.7
1067.3
|
L
 -98.8%
H
3.7
1067.3
|
| Crescent Biopharma Inc |
|
-
|
12.3
|
L
 11.5%
H
11.1
12.5
|
L
 11.3%
H
10.6
12.5
|
L
 -12.6%
H
10.6
14.3
|
L
 20.2%
H
9.8
16.4
|
L
 8.6%
H
7.6
21.4
|
L
 212.7%
H
2.8
21.4
|
L
 -19.5%
H
0.9
21.4
|
L
 -85.6%
H
0.9
123.8
|
| C4 Therapeutics Inc |
|
224.8
|
2.3
|
L
 0.4%
H
2.3
2.5
|
L
 14.3%
H
2.0
2.5
|
L
 -6.1%
H
1.9
2.5
|
L
 10.0%
H
1.9
2.8
|
L
 -33.7%
H
1.1
4.1
|
L
 -72.8%
H
1.1
11.9
|
L
 -94.1%
H
1.1
51.2
|
L
H
1.1
51.2
|
| Compugen Ltd |
|
185.2
|
2.0
|
L
 0.5%
H
1.9
2
|
L
 27.7%
H
1.6
2.0
|
L
 29.4%
H
1.4
2.0
|
L
 -11.6%
H
1.4
2.3
|
L
 -0.5%
H
1.1
2.7
|
L
 86.8%
H
0.5
3.0
|
L
 -85.2%
H
0.5
14.2
|
L
 -62.0%
H
0.5
19.9
|
| Cognition Therapeutics Inc |
|
126.2
|
1.4
|
L
H
1.4
1.4
|
L
 1.4%
H
1.4
1.6
|
L
 -15.4%
H
1.3
1.7
|
L
 -20.6%
H
1.3
2
|
L
 93.2%
H
0.2
3.8
|
L
 -35.6%
H
0.2
3.8
|
L
H
0.2
13.8
|
L
H
0.2
13.8
|
| Co-Diagnostics Inc |
|
4.9
|
2.4
|
L
 -60.5%
H
2.4
6.1
|
L
 -58.6%
H
2.4
6.4
|
L
 -76.9%
H
2.4
10.2
|
L
 -79.6%
H
2.4
46.5
|
L
 -89.7%
H
2.4
46.5
|
L
 -97.4%
H
2.4
99.9
|
L
 -99.2%
H
2.4
620.6
|
L
H
2.4
929.7
|
| Coeptis Therapeutics Holdings Inc |
|
75.6
|
14.2
|
L
 -1.5%
H
14
14.6
|
L
 -6.7%
H
13.7
16.0
|
L
 -6.4%
H
13.6
16.0
|
L
 -8.9%
H
13
21.4
|
L
 77%
H
6.3
21.4
|
L
 -61.3%
H
2.3
43.8
|
L
 38.6%
H
2.3
242.6
|
L
H
2.3
242.6
|
| Cogent Biosciences Inc |
|
5,808.7
|
37.8
|
L
 7.3%
H
35.1
38.4
|
L
 8.8%
H
33.8
38.4
|
L
 -10.1%
H
32.9
42.3
|
L
 133.6%
H
13.8
43.7
|
L
 399.9%
H
3.7
43.7
|
L
 190.4%
H
3.7
43.7
|
L
 216.1%
H
3.7
43.7
|
L
H
1.2
70.6
|
| Caribou Biosciences Inc |
|
148.6
|
1.6
|
L
H
1.6
1.6
|
L
 -7.6%
H
1.5
1.8
|
L
 -11.2%
H
1.5
1.9
|
L
 -33.2%
H
1.5
3.5
|
L
 2.6%
H
0.7
3.5
|
L
 -78.0%
H
0.7
8.6
|
L
H
0.7
32.6
|
L
H
0.7
32.6
|
| Cardiol Therapeutics Inc (Class A) |
|
97.0
|
1.0
|
L
H
1.0
1
|
L
 -3%
H
1.0
1.0
|
L
 -10.2%
H
0.9
1.1
|
L
 -7.6%
H
0.9
1.4
|
L
 -23.6%
H
0.8
1.6
|
L
 19.8%
H
0.5
3.1
|
L
 -71.3%
H
0.5
5.3
|
L
H
0.5
8.5
|
| Curis Inc |
|
11.2
|
0.9
|
L
 -3.3%
H
0.8
0.9
|
L
 -13%
H
0.8
0.9
|
L
 -25%
H
0.8
1.2
|
L
 -40%
H
0.8
1.7
|
L
 -74.1%
H
0.8
3.7
|
L
 -94.0%
H
0.8
20
|
L
 -99.6%
H
0.8
348
|
L
 -99.5%
H
0.8
372
|
| CorMedix Inc |
|
572.0
|
7.3
|
L
 2.8%
H
7.1
7.4
|
L
 -35.5%
H
7.0
11.6
|
L
 -36.8%
H
7.0
13.0
|
L
 -31.4%
H
7.0
13.0
|
L
 -34.7%
H
5.6
17.4
|
L
 63.9%
H
2.6
17.4
|
L
 -15.9%
H
2.6
18.8
|
L
 8.4%
H
0.9
22.7
|
| CRISPR Therapeutics AG |
|
5,433.1
|
57.0
|
L
 1.5%
H
55.3
58.0
|
L
 -2.0%
H
53.4
59.9
|
L
 0.6%
H
52.1
60.7
|
L
 -16.5%
H
48.0
75.1
|
L
 46.7%
H
30.0
78.5
|
L
 14.2%
H
30.0
91.1
|
L
 -70.6%
H
30.0
220.2
|
L
H
11.6
220.2
|
| Champions Oncology Inc |
|
96.4
|
6.9
|
L
 -1.7%
H
6.9
7.0
|
L
 5.0%
H
6.6
7.2
|
L
 3.3%
H
6.1
8.3
|
L
 6.6%
H
6.0
8.3
|
L
 -24.3%
H
5.6
12.0
|
L
 61.4%
H
3.6
12.0
|
L
 -37.2%
H
3.6
14.7
|
L
 87.1%
H
1.1
17.9
|
| Cue Biopharma Inc |
|
31.9
|
0.4
|
L
H
0.3
0.4
|
L
 -5.4%
H
0.3
0.4
|
L
 -28.6%
H
0.2
0.5
|
L
 -57.3%
H
0.2
0.9
|
L
 -73.9%
H
0.2
1.5
|
L
 -89.9%
H
0.2
5.1
|
L
 -97.2%
H
0.2
18.4
|
L
H
0.2
31.7
|
| Cadrenal Therapeutics Inc |
|
19.7
|
8.4
|
L
 -3%
H
8.3
8.8
|
L
 21.4%
H
7.1
8.8
|
L
 -23.6%
H
6.4
12.5
|
L
 -39.9%
H
6.4
14.4
|
L
 -47.4%
H
6.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
L
H
0.4
22.9
|
| Chemomab Therapeutics Ltd (ADR) |
|
10.8
|
1.8
|
L
 -1.7%
H
1.7
1.9
|
L
 -2.8%
H
1.7
1.9
|
L
 -20.7%
H
1.6
2.3
|
L
 -47.6%
H
1.6
3.5
|
L
 -77.8%
H
1.6
8.8
|
L
 -80.5%
H
1.6
10.8
|
L
 -98.7%
H
1.6
675.2
|
L
H
1.6
736
|
| Compass Pathways PLC (ADR) |
|
729.7
|
7.6
|
L
 3.1%
H
7.3
7.7
|
L
 7.8%
H
6.8
8.2
|
L
 12.8%
H
6.1
8.2
|
L
 20.8%
H
4.9
8.2
|
L
 125.5%
H
2.3
8.2
|
L
 -20.4%
H
2.3
12.8
|
L
 -81.9%
H
2.3
58.6
|
L
H
2.3
61.7
|
| Denali Therapeutics Inc |
|
2,837.4
|
18.2
|
L
 0.3%
H
17.9
18.5
|
L
 5.6%
H
16.6
18.5
|
L
 1.1%
H
15.3
18.5
|
L
 21.3%
H
13.8
20.6
|
L
 -7.3%
H
10.6
24.3
|
L
 -37.5%
H
10.6
33.3
|
L
 -76.2%
H
10.6
84.0
|
L
H
10.6
93.9
|
| Dominari Holdings Inc |
|
68.2
|
4.3
|
L
 -0.2%
H
4.3
4.3
|
L
 -0.5%
H
4.2
4.7
|
L
 -4.3%
H
4.2
5.1
|
L
 -31.7%
H
3.7
6.4
|
L
 309.6%
H
1
13.6
|
L
 17.0%
H
0.8
13.6
|
L
 -77.6%
H
0.8
43.4
|
L
 -96.9%
H
0.8
308.4
|
| DarioHealth Corp |
|
79.9
|
11.8
|
L
 0.5%
H
11.8
11.9
|
L
 -12.3%
H
11.6
13.2
|
L
 -0.6%
H
10.0
13.6
|
L
 -20.9%
H
9.0
16.5
|
L
 -25.2%
H
5.9
27.6
|
L
 -90.1%
H
5.9
135.6
|
L
 -96.2%
H
5.9
637
|
L
 -99.6%
H
5.9
3492
|
| Bright Minds Biosciences Inc |
|
885.6
|
91
|
L
 1.8%
H
88.3
91.5
|
L
 -2.4%
H
79.5
99.7
|
L
 8.1%
H
72.0
123.8
|
L
 40.1%
H
50
123.8
|
L
 157.0%
H
23.2
123.8
|
L
 2203.8%
H
0.9
123.8
|
L
H
0.9
123.8
|
L
H
0.9
123.8
|
| Design Therapeutics Inc |
|
564.5
|
9.9
|
L
 3.6%
H
9.6
10.0
|
L
 12.4%
H
8.8
10.2
|
L
 5.1%
H
8.2
10.2
|
L
 52.7%
H
5.3
10.3
|
L
 141.7%
H
2.6
10.3
|
L
 10.1%
H
1.9
10.3
|
L
H
1.9
50.5
|
L
H
1.9
50.5
|
| Precision Biosciences Inc |
|
99.2
|
4.1
|
L
 0.2%
H
4.0
4.2
|
L
 -2.1%
H
3.8
4.6
|
L
 -17.4%
H
3.8
5.0
|
L
 -25.9%
H
3.8
8.8
|
L
 -28.2%
H
3.8
8.8
|
L
 200.7%
H
0.3
19.4
|
L
 -58.0%
H
0.3
19.4
|
L
H
0.3
23.7
|
| Dynavax Tech Corp |
|
1,781.4
|
15.7
|
L
 -0.3%
H
15.7
15.7
|
L
 1.6%
H
15.4
15.7
|
L
 45.1%
H
10.6
15.7
|
L
 56.5%
H
9.7
15.7
|
L
 25.6%
H
9.2
15.7
|
L
 38.1%
H
9.2
15.7
|
L
 207.9%
H
4.9
21.4
|
L
 -31.5%
H
1.8
27.9
|
| Dyne Therapeutics Inc |
|
2,797.4
|
17.0
|
L
 -0.3%
H
16.9
17.3
|
L
 -6.2%
H
16.8
19.9
|
L
 -11.8%
H
16.8
21
|
L
 21.1%
H
13.9
25
|
L
 11.1%
H
6.4
25
|
L
 31.1%
H
6.4
47.5
|
L
 -42.0%
H
4.3
47.5
|
L
H
4.3
47.5
|
| Editas Medicine Inc |
|
215.7
|
2.2
|
L
 5.7%
H
2.1
2.3
|
L
 3.3%
H
2.0
2.3
|
L
 -12.7%
H
2.0
2.6
|
L
 -37.9%
H
2.0
4.3
|
L
 90.5%
H
0.9
4.5
|
L
 -73.8%
H
0.9
11.9
|
L
 -97.0%
H
0.9
84.0
|
L
H
0.9
100.0
|
| Elicio Therapeutics Inc |
|
136.3
|
7.9
|
L
 1.7%
H
7.6
8.1
|
L
 -2.1%
H
7.5
8.6
|
L
 -3.4%
H
7.5
8.8
|
L
 -25.8%
H
7.4
10.7
|
L
 34.8%
H
4.6
12.6
|
L
 -22.5%
H
3.0
24.4
|
L
H
3.0
263
|
L
H
3.0
263
|
| Enliven Therapeutics Inc |
|
1,536.5
|
25.9
|
L
 0.5%
H
24.9
27.4
|
L
 71%
H
14.9
30.0
|
L
 53.6%
H
14.8
30.0
|
L
 25.2%
H
14.8
30.0
|
L
 17.3%
H
13.3
30.0
|
L
 44.5%
H
9.8
30.0
|
L
 -53.0%
H
3.9
59.9
|
L
H
3.9
250.8
|
| Climb Bio Inc |
|
192.4
|
4.0
|
L
 -2.4%
H
3.9
4.2
|
L
 5.8%
H
3.8
5.2
|
L
 34.3%
H
3.1
5.2
|
L
 101.5%
H
1.6
5.2
|
L
 109.9%
H
1.1
5.2
|
L
 -0.7%
H
1.1
11.6
|
L
H
1.1
29.7
|
L
H
1.1
29.7
|
| Enlivex Therapeutics Ltd |
|
225.5
|
1.0
|
L
 8.0%
H
0.9
1.0
|
L
 15.9%
H
0.8
1.0
|
L
 2.2%
H
0.7
1.0
|
L
 -13.6%
H
0.7
1.8
|
L
 -17.4%
H
0.7
2.1
|
L
 -78.3%
H
0.7
4.7
|
L
 -90.9%
H
0.7
29.4
|
L
 -99.1%
H
0.7
318
|
| Enochian Biosciences Inc |
|
-
|
1.0
|
L
 3.2%
H
0.9
1
|
L
 5.4%
H
0.9
1
|
L
 -9.4%
H
0.9
1.1
|
L
 -31.7%
H
0.8
1.7
|
L
 203.1%
H
0.1
1.7
|
L
 -23.6%
H
0.1
2.3
|
L
 -67.9%
H
0.1
13.8
|
L
 -69.7%
H
0.1
13.8
|
| Ensysce Biosciences Inc |
|
3.3
|
0.9
|
L
 -2.2%
H
0.9
1.0
|
L
 -10.9%
H
0.9
1.1
|
L
 -36.6%
H
0.9
1.4
|
L
 -61.2%
H
0.9
2.8
|
L
 -87.5%
H
0.9
9.0
|
L
 -90.3%
H
0.1
18.4
|
L
 -100.0%
H
0.1
5757.6
|
L
H
0.1
5757.6
|
| Equillium Inc |
|
71.2
|
1.2
|
L
 6.4%
H
1.1
1.2
|
L
 -9.3%
H
1.1
1.4
|
L
 -8.6%
H
1.0
1.7
|
L
 -8.6%
H
0.8
1.7
|
L
 67.1%
H
0.3
2.4
|
L
 6.4%
H
0.3
3.3
|
L
 -79.0%
H
0.3
11.3
|
L
H
0.3
27.1
|
| Edgewise Therapeutics Inc |
|
2,930.4
|
27.7
|
L
 10.9%
H
24.7
28.0
|
L
 20.7%
H
23.3
28.0
|
L
 17.2%
H
19.8
28.0
|
L
 88.2%
H
14.3
28.0
|
L
 9.3%
H
10.6
30.5
|
L
 150.5%
H
5.1
38.1
|
L
H
5.1
40.5
|
L
H
5.1
40.5
|
| Evaxion Biotech A/S (ADR) |
|
42.0
|
5.0
|
L
 -1.2%
H
5.0
5.2
|
L
 -0.2%
H
4.9
5.5
|
L
 -18.8%
H
4.6
6.2
|
L
 -19.5%
H
4.6
12.2
|
L
 492.9%
H
1.2
12.2
|
L
 -67.5%
H
0.8
21.1
|
L
H
0.8
250.4
|
L
H
0.8
250.4
|
| Fate Therapeutics Inc |
|
122.3
|
1.1
|
L
 3.9%
H
1.0
1.1
|
L
 5.0%
H
1.0
1.1
|
L
 -7.8%
H
1.0
1.2
|
L
 -23.7%
H
1.0
1.9
|
L
 -17.8%
H
0.7
1.9
|
L
 -80.4%
H
0.7
8.8
|
L
 -99.1%
H
0.7
121.2
|
L
 -59.7%
H
0.7
121.2
|
| Forte Biosciences Inc |
|
411.1
|
32.8
|
L
 1.0%
H
30
34.2
|
L
 39.9%
H
23.1
34.2
|
L
 53.6%
H
20.3
34.2
|
L
 122.5%
H
10.3
34.2
|
L
 105.1%
H
4.9
34.2
|
L
 28.7%
H
4.1
34.2
|
L
 -96.4%
H
4.1
1089.3
|
L
H
0.0
1349.8
|
| 4D Molecular Therapeutics Inc |
|
497.1
|
8.7
|
L
 10.7%
H
7.9
8.7
|
L
 21%
H
7.1
8.7
|
L
 -19.7%
H
7.0
11.8
|
L
 -10.0%
H
7.0
12.3
|
L
 82.8%
H
2.2
12.3
|
L
 -60.5%
H
2.2
36.3
|
L
 -80.2%
H
2.2
55.1
|
L
H
2.2
55.1
|
| Foghorn Therapeutics Inc |
|
352.3
|
6.2
|
L
 -6.7%
H
5.9
6.8
|
L
 26.4%
H
5.0
7.0
|
L
 40.3%
H
4.2
7.0
|
L
 45.2%
H
3.3
7.0
|
L
 42.6%
H
2.9
7.0
|
L
 -28.5%
H
2.7
10.2
|
L
 -68.5%
H
2.7
25.1
|
L
H
2.7
28.3
|
| Frequency Therapeutics Inc |
|
-
|
9.0
|
L
 0.6%
H
8.6
9.5
|
L
 8.8%
H
8.1
9.6
|
L
 9.2%
H
7.6
9.6
|
L
 -80.3%
H
5.2
55.9
|
L
 -40.5%
H
5.2
55.9
|
L
 -96.0%
H
5.2
279.5
|
L
 -99.5%
H
5.2
2918.5
|
L
H
5.2
2918.5
|
| First Wave BioPharma Inc |
|
6.2
|
4.0
|
L
 -2.5%
H
3.8
4.1
|
L
 -14.1%
H
3.8
5.1
|
L
 34.4%
H
1.9
5.3
|
L
 -29.8%
H
1.9
5.8
|
L
 840.5%
H
0.4
5.8
|
L
 -95.7%
H
0.4
149.8
|
L
 -100.0%
H
0.4
110458.7
|
L
H
0.4
235200
|
| Galectin Therapeutics Inc |
|
192.1
|
3.0
|
L
 -2.9%
H
2.9
3.1
|
L
 -13.6%
H
2.9
3.7
|
L
 -52.3%
H
2.9
7.1
|
L
 -41.6%
H
2.9
7.1
|
L
 168.5%
H
1.1
7.1
|
L
 161.4%
H
0.7
7.1
|
L
 36.1%
H
0.7
7.1
|
L
 132.8%
H
0.5
9.5
|
| Gain Therapeutics Inc |
|
85.0
|
2.2
|
L
 -0.9%
H
2.2
2.3
|
L
 -13.3%
H
2.0
2.7
|
L
 -46.6%
H
2.0
4.3
|
L
 16.3%
H
1.7
4.3
|
L
 0.9%
H
1.4
4.3
|
L
 -43.0%
H
0.9
6.2
|
L
H
0.9
17.9
|
L
H
0.9
17.9
|
| CytoMed Therapeutics Ltd |
|
10.6
|
0.9
|
L
 -26.2%
H
0.9
1.2
|
L
 -35.3%
H
0.9
1.4
|
L
 -45.8%
H
0.9
1.7
|
L
 -53.4%
H
0.9
3.7
|
L
 -60.2%
H
0.9
3.7
|
L
H
0.9
9.3
|
L
H
0.9
9.3
|
L
H
0.9
9.3
|
| Geron Corp |
|
842.6
|
1.3
|
L
 0.8%
H
1.3
1.3
|
L
H
1.3
1.5
|
L
 -2.9%
H
1.3
1.5
|
L
 3.9%
H
1.0
1.5
|
L
 -55.7%
H
1.0
3.1
|
L
 -58.2%
H
1.0
5.3
|
L
 -18.5%
H
1.0
5.3
|
L
 -59.5%
H
0.8
7.0
|
| Gilead Sciences |
|
153,186.7
|
123.5
|
L
 1.4%
H
121.4
123.5
|
L
 1.7%
H
119.3
125.1
|
L
 3.2%
H
116.9
127.4
|
L
 4.5%
H
114.0
128.7
|
L
 37.3%
H
89.8
128.7
|
L
 43.1%
H
62.1
128.7
|
L
 100.6%
H
57.2
128.7
|
L
 33.4%
H
56.6
128.7
|
| Greenwich LifeSciences Inc |
|
439.2
|
31.7
|
L
 9.2%
H
28.5
32.9
|
L
 54.4%
H
20.4
32.9
|
L
 195.4%
H
10
32.9
|
L
 207.8%
H
7.8
32.9
|
L
 158.6%
H
7.8
32.9
|
L
 95.0%
H
7.6
32.9
|
L
 -11.3%
H
6.8
69.8
|
L
H
3.3
158.1
|
| Monte Rosa Therapeutics Inc |
|
1,850.4
|
24.3
|
L
 1.2%
H
23.2
24.5
|
L
 51.6%
H
21.1
25.8
|
L
 48.8%
H
13.7
25.8
|
L
 133.4%
H
8.9
25.8
|
L
 328.8%
H
3.5
25.8
|
L
 210.8%
H
2.4
25.8
|
L
H
2.4
45.6
|
L
H
2.4
45.6
|
| Geovax Labs Inc |
|
5.1
|
2.9
|
L
 -15.8%
H
2.9
3.4
|
L
 -46.2%
H
2.9
5.5
|
L
 -68.8%
H
2.9
8.8
|
L
 -78.9%
H
2.9
15.8
|
L
 -94.5%
H
2.9
57.8
|
L
 -99.1%
H
2.9
521.3
|
L
 -99.8%
H
2.9
3266.3
|
L
 -100.0%
H
2.9
379518072.3
|
| Graphite Bio Inc |
|
966.7
|
16.6
|
L
 6.6%
H
15.6
16.6
|
L
 -1.5%
H
14.4
17.5
|
L
 -8.5%
H
14.4
19.6
|
L
 -57.0%
H
14.4
43.0
|
L
 -38.1%
H
14.4
50.4
|
L
 -83.1%
H
14.4
413
|
L
H
14.4
1666
|
L
H
14.4
1666
|
| Galapagos NV (ADR) |
|
2,244.5
|
34.1
|
L
 2.4%
H
33.3
34.1
|
L
 4.7%
H
32.4
34.1
|
L
 7.5%
H
30.7
34.1
|
L
 0.4%
H
29.8
35
|
L
 40.5%
H
22.4
37.8
|
L
 -27.1%
H
22.4
48.1
|
L
 -66.1%
H
22.4
113.7
|
L
 -36.4%
H
22.4
274.0
|
| Halozyme Therapeutics Inc |
|
8,681.0
|
73.8
|
L
 3%
H
71.4
73.8
|
L
 0.9%
H
71.2
75.6
|
L
 18.7%
H
61.7
75.6
|
L
 13%
H
61.2
75.6
|
L
 36.4%
H
47.5
79.5
|
L
 46.6%
H
29.9
79.5
|
L
 63.6%
H
29.9
79.5
|
L
 633.8%
H
7.0
79.5
|
| HCW Biologics Inc |
|
3.8
|
1.2
|
L
 -2.5%
H
1.1
1.2
|
L
 -2.5%
H
1.1
1.4
|
L
 -35.4%
H
1.0
1.9
|
L
 -72.3%
H
1.0
4.6
|
L
 -92.0%
H
0.2
41.2
|
L
 -98.6%
H
0.2
100.8
|
L
H
0.2
311
|
L
H
0.2
311
|
| Hillstream BioPharma Inc |
|
33.9
|
2.9
|
L
 -4.0%
H
2.8
3.1
|
L
 -6.5%
H
2.8
3.1
|
L
 20.9%
H
2.2
3.6
|
L
 -1.0%
H
2.2
6.9
|
L
 117.3%
H
1.1
9.1
|
L
 -72.6%
H
1.1
132.8
|
L
H
1.1
132.8
|
L
H
1.1
132.8
|
| Heron Therapeutics Inc |
|
273.2
|
1.5
|
L
 0.7%
H
1.5
1.5
|
L
 22.1%
H
1.2
1.6
|
L
 8.8%
H
1.1
1.6
|
L
 14.6%
H
1
1.6
|
L
 -3.3%
H
1
2.7
|
L
 -53.0%
H
0.5
3.9
|
L
 -91.8%
H
0.5
20.5
|
L
 -93.4%
H
0.5
42.9
|
| Quantum BioPharma Ltd (Class B) (Sub Voting) |
|
27.6
|
7.2
|
L
 -3.5%
H
6.9
7.3
|
L
 2.3%
H
6.9
7.7
|
L
 -23.6%
H
6.5
11.5
|
L
 -52.8%
H
5.6
16.4
|
L
 112.1%
H
2.9
38.3
|
L
 -88.2%
H
2.7
136.5
|
L
 -94.5%
H
2.7
288.6
|
L
H
2.7
11431.9
|
| Humacyte Inc |
|
216.2
|
1.1
|
L
 0.9%
H
1.1
1.1
|
L
 3.7%
H
1.1
1.3
|
L
 -14.5%
H
0.9
1.3
|
L
 -36.4%
H
0.9
1.9
|
L
 -74.5%
H
0.9
4.9
|
L
 -55.2%
H
0.9
10.0
|
L
 -89.0%
H
0.9
17.5
|
L
H
0.9
17.5
|
| Immucell Corp |
|
60.7
|
6.7
|
L
 0.9%
H
6.6
6.8
|
L
 5.7%
H
6.2
6.9
|
L
 8.1%
H
5.8
7.1
|
L
 2.0%
H
4.5
7.1
|
L
 25.9%
H
4.3
7.6
|
L
 -9.6%
H
3.3
7.7
|
L
 7.2%
H
3.3
13.2
|
L
 -13.3%
H
3.3
13.2
|
| InflaRx N.V. |
|
69.8
|
1.0
|
L
 3%
H
1
1.1
|
L
 -12.0%
H
1
1.2
|
L
 -1.9%
H
1.0
1.2
|
L
 -17.6%
H
0.9
1.9
|
L
 -56.0%
H
0.7
2.8
|
L
 -60.8%
H
0.7
7.3
|
L
 -83.7%
H
0.7
7.3
|
L
H
0.7
53.1
|
| ImageneBio Inc |
|
77.3
|
6.9
|
L
 2.1%
H
6.7
7.0
|
L
 4.4%
H
6.6
7.1
|
L
 6.3%
H
5.7
7.2
|
L
 -10.1%
H
5.7
9.1
|
L
 -62.6%
H
5.7
19.2
|
L
 -82.3%
H
5.7
91.7
|
L
H
5.7
451.3
|
L
H
5.7
451.3
|
| Illumina Inc |
|
21,991.0
|
143.9
|
L
 -2.1%
H
140.2
148.6
|
L
 -2.2%
H
139.8
151.3
|
L
 6.7%
H
129.3
151.3
|
L
 51.5%
H
88
151.3
|
L
 -0.2%
H
68.7
153.1
|
L
 -28.4%
H
68.7
238.6
|
L
 -60.2%
H
68.7
555.8
|
L
 -12.5%
H
68.7
555.8
|
| Immunome Inc |
|
2,299.4
|
20.8
|
L
 3.5%
H
20.1
21.2
|
L
 5.5%
H
19.2
22.0
|
L
 6.5%
H
19.2
25.3
|
L
 46.3%
H
13.5
25.3
|
L
 107.6%
H
5.2
25.3
|
L
 421%
H
4.0
31.0
|
L
 57.9%
H
2.1
63.8
|
L
H
2.1
63.8
|
| Imunon Inc |
|
12.7
|
3.7
|
L
 -1.8%
H
3.6
3.9
|
L
 -5.6%
H
3.5
4.0
|
L
 -10.1%
H
3.0
4.2
|
L
 -25.7%
H
3.0
5.3
|
L
 -72.9%
H
3.0
47.4
|
L
 -84.5%
H
3.0
54.8
|
L
 -98.2%
H
3.0
783
|
L
 -99.9%
H
3.0
5607
|
| Immatics N.V |
|
1,320.5
|
9.9
|
L
 5.0%
H
9.3
9.9
|
L
 2.6%
H
8.9
10.2
|
L
 -1.9%
H
8.9
10.9
|
L
 -2.4%
H
8.7
12.4
|
L
 57.6%
H
3.3
12.4
|
L
 11.9%
H
3.3
13.8
|
L
 -9.7%
H
3.3
18.4
|
L
H
3.3
18.4
|
| Immunovant Inc |
|
5,393.5
|
26.8
|
L
 2.3%
H
25.7
26.8
|
L
 3.4%
H
25.2
27.8
|
L
 1.3%
H
24.7
27.8
|
L
 54.3%
H
16.8
27.8
|
L
 17.7%
H
12.7
27.8
|
L
 43.9%
H
12.7
45.6
|
L
 -39.4%
H
3.1
46.5
|
L
H
3.1
53.8
|
| IN8bio Inc |
|
21.7
|
2.2
|
L
 2.3%
H
2.2
2.3
|
L
 -10.1%
H
2.1
2.6
|
L
 32.1%
H
1.2
2.6
|
L
 2.3%
H
1.2
2.6
|
L
 593.8%
H
0.1
4.2
|
L
 -3.9%
H
0.1
4.2
|
L
H
0.1
10.3
|
L
H
0.1
10.3
|
| Inhibrx Inc |
|
3,586.0
|
75.7
|
L
 3.3%
H
71.2
75.7
|
L
 -0.5%
H
69.5
80
|
L
 -4.9%
H
69.5
94.6
|
L
 120.2%
H
28.2
94.6
|
L
 454.9%
H
10.8
94.6
|
L
 219.9%
H
10.8
94.6
|
L
 95.2%
H
7.7
94.6
|
L
H
7.7
94.6
|
| MiNK Therapeutics Inc |
|
54.9
|
11.7
|
L
 -0.9%
H
11.4
11.8
|
L
 -2.8%
H
11.4
12.7
|
L
 -5.8%
H
10.8
12.7
|
L
 -17.0%
H
10.5
15.4
|
L
 51.2%
H
0.9
76
|
L
 -50.4%
H
0.9
76
|
L
H
0.9
221.6
|
L
H
0.9
221.6
|
| INmune Bio Inc |
|
40.4
|
1.5
|
L
 1.3%
H
1.5
1.5
|
L
 -2.6%
H
1.4
1.7
|
L
 -24.4%
H
1.4
2.0
|
L
 -16.9%
H
1.4
2.3
|
L
 -76.8%
H
1.4
11.6
|
L
 -82.8%
H
1.4
14.7
|
L
 -93.7%
H
1.4
30.4
|
L
H
1.4
30.4
|
| IO Biotech Inc |
|
38.9
|
0.5
|
L
 3.9%
H
0.5
0.6
|
L
 -15.6%
H
0.5
0.7
|
L
 -33.3%
H
0.5
0.8
|
L
 -6.9%
H
0.5
1.2
|
L
 -37.2%
H
0.3
2.8
|
L
 -76.9%
H
0.3
3.3
|
L
H
0.3
17.9
|
L
H
0.3
17.9
|
| Iovance Biotherapeutics Inc |
|
944.8
|
2.4
|
L
 1.3%
H
2.3
2.4
|
L
 -6.7%
H
2.3
2.8
|
L
 8.2%
H
2.1
3.0
|
L
 11.2%
H
1.8
3.0
|
L
 -58.8%
H
1.6
6.5
|
L
 -62.5%
H
1.6
18.3
|
L
 -95.3%
H
1.6
54.2
|
L
 -55.8%
H
1.6
54.2
|
| Century Therapeutics Inc |
|
171.3
|
2.0
|
L
 -8.8%
H
1.9
2.2
|
L
 117.8%
H
0.9
2.2
|
L
 250%
H
0.5
2.2
|
L
 256.4%
H
0.4
2.2
|
L
 102.1%
H
0.3
2.2
|
L
 -59.9%
H
0.3
5.5
|
L
H
0.3
32.9
|
L
H
0.3
32.9
|
| Disc Medicine Inc |
|
2,908.6
|
77.1
|
L
 2.1%
H
74.7
78.1
|
L
 -0.4%
H
74.7
81.9
|
L
 -16.1%
H
71.4
92.6
|
L
 7.1%
H
71.0
99.5
|
L
 31.2%
H
30.8
99.5
|
L
 300.3%
H
18.3
99.5
|
L
 -40.5%
H
11.6
190.9
|
L
H
11.6
190.9
|
| Invivyd Inc |
|
693.7
|
2.5
|
L
 5.1%
H
2.3
2.5
|
L
 3.4%
H
2.2
2.8
|
L
 6.0%
H
2.2
3.0
|
L
 30.9%
H
1.4
3.1
|
L
 515%
H
0.4
3.1
|
L
 10.8%
H
0.4
5.2
|
L
H
0.4
78.8
|
L
H
0.4
78.8
|
| Immunocore Holdings PLC (ADR) |
|
1,689.2
|
33.4
|
L
 3.5%
H
32.2
34.7
|
L
 1.8%
H
31.8
35.8
|
L
 -9.2%
H
31.8
38.4
|
L
 3.3%
H
30.5
40.7
|
L
 11.3%
H
23.2
40.7
|
L
 -47.4%
H
23.2
77.0
|
L
H
18.4
77.0
|
L
H
18.4
77.0
|
| Immutep Ltd (ADR) |
|
453.4
|
3.1
|
L
 -1.3%
H
3.1
3.2
|
L
 4.8%
H
2.9
3.2
|
L
 19.4%
H
2.4
3.3
|
L
 54.8%
H
1.7
3.5
|
L
 58.8%
H
1.3
3.5
|
L
 53.2%
H
1.3
3.9
|
L
 -13.5%
H
1.3
5.4
|
L
 -7.2%
H
0.5
8.0
|
| Inventiva (ADR) |
|
1,126.6
|
5.9
|
L
 2.8%
H
5.8
6.0
|
L
 29.3%
H
4.8
6.0
|
L
 31.6%
H
4.1
6.0
|
L
 27.3%
H
3.6
8.0
|
L
 170.5%
H
2.1
8.0
|
L
 -3.0%
H
1.5
8.0
|
L
 -65.1%
H
1.5
19.1
|
L
H
1.5
19.1
|
| Janux Therapeutics Inc |
|
845.7
|
14.1
|
L
 2.0%
H
13.7
14.3
|
L
 4.6%
H
13.5
14.3
|
L
 -8.1%
H
13.3
15.6
|
L
 -46.5%
H
13.3
35.3
|
L
 -68.8%
H
13.3
47.6
|
L
 -31.6%
H
5.7
71.7
|
L
H
5.7
71.7
|
L
H
5.7
71.7
|
| Jasper Therapeutics Inc |
|
45.6
|
1.6
|
L
 4.5%
H
1.5
1.6
|
L
 -14.2%
H
1.4
2.1
|
L
 -7.9%
H
1.4
2.1
|
L
 -32.1%
H
1.4
2.7
|
L
 -75.6%
H
1.4
7.2
|
L
 -8.4%
H
0.4
31.0
|
L
H
0.4
31.0
|
L
H
0.4
31.0
|
| Kamada Ltd |
|
455.1
|
7.9
|
L
 0.1%
H
7.9
8.0
|
L
 6.2%
H
7.6
8.2
|
L
 12.4%
H
6.9
8.2
|
L
 14.7%
H
6.6
8.2
|
L
 9.6%
H
5.5
9.2
|
L
 55.3%
H
4.1
9.2
|
L
 11.8%
H
3.7
9.2
|
L
 87.4%
H
3.3
13.3
|
| Kodiak Sciences Inc |
|
1,755.1
|
28.8
|
L
 1.5%
H
28
29.4
|
L
 14.8%
H
25.2
29.4
|
L
 20.8%
H
21.5
31.2
|
L
 147.8%
H
10.9
31.2
|
L
 268.1%
H
1.9
31.2
|
L
 247.2%
H
1.4
31.2
|
L
 -81.3%
H
1.4
171.2
|
L
H
1.4
171.2
|
| Krystal Biotech Inc |
|
8,558.6
|
295.2
|
L
 1.1%
H
287.6
295.8
|
L
 18.4%
H
245.7
295.8
|
L
 20.6%
H
231.7
295.8
|
L
 59.8%
H
181.4
295.8
|
L
 96.4%
H
122.8
295.8
|
L
 255.8%
H
70.5
295.8
|
L
 353.7%
H
38.9
295.8
|
L
H
8.0
295.8
|
| TuHURA Biosciences Inc |
|
41.8
|
0.7
|
L
 1.4%
H
0.7
0.8
|
L
 1.4%
H
0.7
0.8
|
L
 -27.5%
H
0.7
1.0
|
L
 -69.6%
H
0.7
2.6
|
L
 -82.8%
H
0.7
5.3
|
L
 -99.7%
H
0.2
267.8
|
L
 -100.0%
H
0.2
5862.5
|
L
 -100.0%
H
0.2
190225
|
| Kura Oncology Inc |
|
809.3
|
9.3
|
L
 1.0%
H
9.0
9.4
|
L
 -2.5%
H
8.9
10.4
|
L
 -9%
H
8.9
11.3
|
L
 -6.3%
H
8.8
12.5
|
L
 28.5%
H
5.4
12.5
|
L
 -35.0%
H
5.4
24.2
|
L
 -72.6%
H
5.4
36.3
|
L
 37.0%
H
2.5
43
|
| Kymera Therapeutics Inc |
|
6,026.3
|
75.3
|
L
 1.6%
H
72.7
76.7
|
L
 2.6%
H
71.5
77.9
|
L
 -16%
H
69.1
90.3
|
L
 25.8%
H
55.3
103
|
L
 102.4%
H
19.4
103
|
L
 118.1%
H
9.6
103
|
L
 -5.4%
H
9.6
103
|
L
H
9.6
103
|
| Kezar Life Sciences Inc |
|
45.6
|
6.2
|
L
 0.2%
H
6.2
6.3
|
L
 -0.5%
H
6.0
6.5
|
L
 -0.3%
H
6.0
6.5
|
L
 45.0%
H
4.1
6.5
|
L
 -1.3%
H
3.5
6.7
|
L
 -90.9%
H
0.7
74.4
|
L
 -88.6%
H
0.7
185.5
|
L
H
0.7
363.3
|
| Longeveron Inc (Class A) |
|
11.7
|
0.6
|
L
H
0.5
0.6
|
L
 -6.8%
H
0.5
0.6
|
L
 -9.8%
H
0.5
0.6
|
L
 -31.3%
H
0.5
0.9
|
L
 -68.9%
H
0.5
1.9
|
L
 -98.5%
H
0.5
45.8
|
L
H
0.5
450
|
L
H
0.5
450
|
| Lixte biotech Holdings Inc |
|
31.1
|
3.6
|
L
 6.9%
H
3.3
3.6
|
L
 0.3%
H
3.3
4.0
|
L
 -11.9%
H
3.3
4.3
|
L
 -17.7%
H
3.3
5.0
|
L
 48.1%
H
0.6
6.3
|
L
 -37.4%
H
0.6
27
|
L
 -89.0%
H
0.6
71.9
|
L
 -80.2%
H
0.6
110.4
|
| Leap Therapeutics Inc |
|
67.4
|
1.2
|
L
 14.4%
H
1.0
1.3
|
L
H
0.9
1.3
|
L
 -17.4%
H
0.9
1.4
|
L
 98.3%
H
0.4
3.7
|
L
 -61.6%
H
0.2
3.7
|
L
 -79.6%
H
0.2
10.2
|
L
 -94.5%
H
0.2
41.7
|
L
H
0.2
102.5
|
| Larimar Therapeutics Inc |
|
282.5
|
3.4
|
L
 2.1%
H
3.3
3.6
|
L
 0.9%
H
3.1
3.6
|
L
 -16.1%
H
3.1
4.2
|
L
 -20%
H
3.1
4.5
|
L
 -2.3%
H
1.6
5.4
|
L
 -26.9%
H
1.6
13.7
|
L
 -82.7%
H
1.5
20.6
|
L
 -95.5%
H
1.5
148.3
|
| Lyell Immunopharma Inc |
|
512.4
|
24.1
|
L
 1.7%
H
23.4
24.4
|
L
 -6.3%
H
22.8
26.5
|
L
 -30.0%
H
22.8
45
|
L
 43.3%
H
15.7
45
|
L
 103.0%
H
7.7
45
|
L
 -62.7%
H
7.7
79.4
|
L
H
7.7
396.8
|
L
H
7.7
396.8
|
| Microbot Medical Inc |
|
144.4
|
2.2
|
L
 1.4%
H
2.1
2.2
|
L
 0.9%
H
2.1
2.2
|
L
 -10.8%
H
2.0
2.5
|
L
 -28.6%
H
1.7
3.0
|
L
 20.8%
H
1.3
4.7
|
L
 -41.4%
H
0.8
4.7
|
L
 -72.9%
H
0.8
10.7
|
L
 -99.6%
H
0.8
729
|
| Seres Therapeutics Inc |
|
143.9
|
15.9
|
L
 -0.4%
H
15.8
16.4
|
L
 2.3%
H
14.9
16.4
|
L
 -6.1%
H
14.0
17.5
|
L
 -17.3%
H
12.5
30.0
|
L
 1840.2%
H
0.4
30.0
|
L
 190.3%
H
0.4
30.0
|
L
 -38.5%
H
0.4
30.0
|
L
 -43.6%
H
0.4
38.5
|
| MeiraGTx Holdings PLC |
|
596.4
|
7.4
|
L
 0.4%
H
7.3
7.5
|
L
 -1.3%
H
7
8.1
|
L
 -16.9%
H
7
9.2
|
L
 -5.4%
H
7
9.7
|
L
 25.4%
H
4.6
9.7
|
L
 6.0%
H
3.5
9.7
|
L
 -54.0%
H
3.5
24.9
|
L
H
3.5
30.2
|
| Mineralys Therapeutics Inc |
|
2,598.2
|
32.8
|
L
 -0.3%
H
32.0
33.6
|
L
 -8.1%
H
31.7
37.7
|
L
 -11.0%
H
31.7
38.4
|
L
 -23.7%
H
31.7
47.7
|
L
 250.8%
H
8.2
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
L
H
5.9
47.7
|
| Monopar Therapeutics Inc |
|
461.9
|
69.1
|
L
 3.1%
H
65.3
69.2
|
L
 13.2%
H
57.9
69.2
|
L
 -7.4%
H
56.2
77.5
|
L
 -32.3%
H
56.2
104
|
L
 169.1%
H
24
105
|
L
 406.0%
H
1.4
105
|
L
 115.7%
H
1.4
105
|
L
H
1.4
240
|
| Marker Therapeutics Inc |
|
30.3
|
1.8
|
L
 6.4%
H
1.6
1.8
|
L
 -2.2%
H
1.6
2.5
|
L
 23.8%
H
1.3
2.5
|
L
 78.4%
H
0.8
2.5
|
L
 -33.6%
H
0.8
4.1
|
L
 -48.7%
H
0.7
9.7
|
L
 -91.3%
H
0.7
37.7
|
L
 -96.6%
H
0.7
135.5
|
| Moderna |
|
15,758.3
|
40.3
|
L
 1.8%
H
39.3
42.0
|
L
 13.1%
H
32.4
42.0
|
L
 36.9%
H
28.7
42.0
|
L
 50.8%
H
22.3
42.0
|
L
 14.7%
H
22.3
45.4
|
L
 -79.0%
H
22.3
207.5
|
L
 -67.5%
H
22.3
497.5
|
L
H
11.5
497.5
|
| Maravai LifeSciences Holdings Inc (Class A) |
|
571.4
|
3.9
|
L
 -2.0%
H
3.9
4.0
|
L
 1.6%
H
3.8
4.1
|
L
 9.4%
H
3.2
4.1
|
L
 19.4%
H
2.5
4.1
|
L
 -20.2%
H
1.7
6.1
|
L
 -71.5%
H
1.7
16.9
|
L
 -85.5%
H
1.7
63.6
|
L
H
1.7
63.6
|
| MaxCyte Inc |
|
136.5
|
1.3
|
L
 -2.3%
H
1.3
1.3
|
L
 -14.7%
H
1.3
1.5
|
L
 -15.8%
H
1.3
1.7
|
L
 -20%
H
1.3
1.9
|
L
 -73.9%
H
1.3
5.2
|
L
 -76.7%
H
1.3
6.0
|
L
 -21.5%
H
1.3
17.4
|
L
H
1.3
17.4
|
| Mainz Biomed N.V. |
|
10.2
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -16.3%
H
1.1
1.4
|
L
 9.7%
H
1
1.5
|
L
 -28.0%
H
0.9
2.1
|
L
 -75.8%
H
0.9
8.2
|
L
 -99.6%
H
0.9
314
|
L
H
0.9
1200
|
L
H
0.9
1200
|
| Mesoblast Ltd (ADR) |
|
2,275.4
|
17.7
|
L
 -0.5%
H
17.5
17.8
|
L
 -4.8%
H
17.4
21.5
|
L
 -2.2%
H
17.4
21.5
|
L
 -2.5%
H
14.1
21.5
|
L
 2.9%
H
9.6
21.5
|
L
 439.0%
H
1.0
22
|
L
 74.4%
H
1.0
22
|
L
 195.7%
H
1.0
22
|
| Molecular Partners AG (ADR) |
|
154.5
|
4.1
|
L
H
4.1
4.3
|
L
 -5.7%
H
4.1
4.5
|
L
 -4.4%
H
3.9
4.6
|
L
 9.0%
H
3.5
4.8
|
L
 -23.5%
H
3.4
5.9
|
L
 -39.3%
H
3.3
12.7
|
L
 -80.1%
H
3.3
32.0
|
L
 -87.6%
H
3.3
34.5
|
| Mereo Biopharma Grp PLC (ADR) |
|
111.4
|
0.7
|
L
 6.1%
H
0.7
0.8
|
L
 84.2%
H
0.4
0.8
|
L
 -67.7%
H
0.2
2.4
|
L
 -65%
H
0.2
2.4
|
L
 -79.0%
H
0.2
3.4
|
L
 -21.3%
H
0.2
5.0
|
L
 -78.8%
H
0.2
5.0
|
L
H
0.2
8.5
|
| Nautilus biotech Inc |
|
246.3
|
2.0
|
L
 -0.5%
H
1.9
2.0
|
L
 4.3%
H
1.9
2.3
|
L
 5.4%
H
1.8
2.3
|
L
 119.1%
H
0.8
2.5
|
L
 6.0%
H
0.6
2.5
|
L
 -5.3%
H
0.6
4.7
|
L
 -83.1%
H
0.6
25.9
|
L
H
0.6
25.9
|
| Nkarta Inc |
|
147.0
|
2.1
|
L
 1.0%
H
2.0
2.1
|
L
 7.3%
H
1.9
2.2
|
L
 10.1%
H
1.7
2.2
|
L
 -8.4%
H
1.7
2.7
|
L
 -10.4%
H
1.3
2.7
|
L
 -62.8%
H
1.3
16.2
|
L
 -96.2%
H
1.3
58.8
|
L
H
1.3
79.2
|
| Neoleukin Therapeutics Inc |
|
-
|
17.0
|
L
 -1.9%
H
16.5
17.3
|
L
 -7.4%
H
16.5
19.8
|
L
 -19.0%
H
16.5
23.0
|
L
 -46.4%
H
16.5
37.3
|
L
 -5.8%
H
14.7
37.3
|
L
 45.1%
H
9.8
37.3
|
L
 -93.4%
H
7.5
298
|
L
 -89.4%
H
7.5
399.4
|
| 9 Meters Biopharma Inc |
|
-
|
7.9
|
L
 0.3%
H
7.8
8.0
|
L
 6.5%
H
7.4
8.0
|
L
 9.3%
H
7.1
8.0
|
L
 13.3%
H
6.4
8.0
|
L
 10.4%
H
6.2
8.0
|
L
 237.3%
H
0.0
8.0
|
L
 -69.1%
H
0.0
45.2
|
L
H
0.0
1010
|
| MetaVia Inc |
|
14.6
|
6.3
|
L
 -18.6%
H
6.3
7.5
|
L
 -22.1%
H
6.3
9.1
|
L
 -32.2%
H
6.3
10
|
L
 -42.1%
H
6.1
14.9
|
L
 -71.5%
H
6.1
23.9
|
L
 -90.7%
H
6.1
83.6
|
L
 -100.0%
H
6.1
17344.8
|
L
H
6.1
1424940
|
| Intellia Therapeutics Inc |
|
1,406.2
|
12.1
|
L
 3.4%
H
11.7
12.3
|
L
 24.8%
H
9.8
12.3
|
L
 34.6%
H
8.7
12.3
|
L
 -48.9%
H
8.0
28.3
|
L
 20.8%
H
5.9
28.3
|
L
 -67.7%
H
5.9
47.5
|
L
 -84.0%
H
5.9
202.7
|
L
H
5.9
202.7
|
| Nuvalent Inc (Class A) |
|
8,365.2
|
107.7
|
L
 6.5%
H
99.4
108.5
|
L
 10.8%
H
97.4
108.5
|
L
 2.8%
H
95.5
108.5
|
L
 20.0%
H
84.6
112.9
|
L
 49.9%
H
55.5
112.9
|
L
 232.2%
H
23.1
113.5
|
L
H
7.1
113.5
|
L
H
7.1
113.5
|
| Novavax Inc |
|
1,340.6
|
8.3
|
L
 -4.8%
H
7.9
8.5
|
L
 10.9%
H
7.2
8.8
|
L
 25.6%
H
6.4
8.8
|
L
 -4.3%
H
6.2
9.3
|
L
 -4.1%
H
5.0
10.6
|
L
 -32.9%
H
3.5
23.9
|
L
 -93.5%
H
3.5
331.7
|
L
 -93.1%
H
3.5
331.7
|
| NuCana PLC (ADR) |
|
14.1
|
3.4
|
L
 -4.0%
H
3.4
3.5
|
L
 -8.4%
H
3.3
3.8
|
L
 -8.9%
H
3.2
3.8
|
L
 -41.4%
H
3.1
6.1
|
L
 -100.0%
H
2.8
53600
|
L
 -100.0%
H
2.8
1750000
|
L
 -100.0%
H
2.8
7770000
|
L
H
2.8
32000000
|
| Insight Molecular Diagnostics Inc |
|
196.9
|
6.9
|
L
 -5.0%
H
6.6
7.3
|
L
 -7.0%
H
6.6
7.5
|
L
 31.6%
H
4.7
7.5
|
L
 76.2%
H
3.8
8.5
|
L
 230.3%
H
1.9
8.5
|
L
 -29.6%
H
1.9
10.0
|
L
 -89.9%
H
1.9
131.4
|
L
 -90.7%
H
1.9
159
|
| OKYO Pharma Ltd - Ordinary Shares - New |
|
106.8
|
2.8
|
L
 -8.7%
H
2.8
3.2
|
L
 34.0%
H
2.1
3.2
|
L
 37.9%
H
1.8
3.2
|
L
 42%
H
1.7
3.2
|
L
 175.7%
H
0.9
3.4
|
L
 42.7%
H
0.8
7
|
L
H
0.8
7
|
L
H
0.8
7
|
| Oncolytics Biotech Inc |
|
108.7
|
1.0
|
L
 1%
H
1.0
1.0
|
L
 5.2%
H
0.9
1.0
|
L
 2.0%
H
0.9
1.1
|
L
 -13.7%
H
0.9
1.3
|
L
 21.7%
H
0.3
1.5
|
L
 -38.8%
H
0.3
3.4
|
L
 -64.9%
H
0.3
4.8
|
L
 -62.6%
H
0.3
8.5
|
| Traws Pharma Inc |
|
13.2
|
1.7
|
L
 2.5%
H
1.5
1.7
|
L
 26.9%
H
1.2
1.7
|
L
 -29.2%
H
1.1
2.4
|
L
 -43.1%
H
1.1
3.2
|
L
 -77.5%
H
1.0
8.6
|
L
 -92.5%
H
1.0
37.3
|
L
 -99.4%
H
1.0
723.8
|
L
 -100.0%
H
1.0
45956.3
|
| VivoSim Labs Inc |
|
5.2
|
2.0
|
L
H
2.0
2.1
|
L
 -1.5%
H
1.9
2.3
|
L
 -9.5%
H
1.7
2.3
|
L
 -32.1%
H
1.7
3.2
|
L
 -53.6%
H
0.3
22.0
|
L
 -90.9%
H
0.3
40.8
|
L
 -98.7%
H
0.3
287.0
|
L
 -99.6%
H
0.3
1197.6
|
| Passage Bio Inc |
|
49.2
|
15.5
|
L
 8.5%
H
14.6
16
|
L
 -16.1%
H
13.3
20
|
L
 58.0%
H
8.6
20
|
L
 78.1%
H
6.2
20
|
L
 20.9%
H
5.1
20
|
L
 -52.8%
H
5.1
35.8
|
L
 -97.2%
H
5.1
617.4
|
L
H
5.1
764.6
|
| Vaxcyte Inc |
|
6,354.2
|
48.5
|
L
 5.5%
H
45.5
49.6
|
L
 8.2%
H
44.2
49.6
|
L
 9.1%
H
42.4
49.6
|
L
 10.8%
H
39.9
50.3
|
L
 -40.2%
H
27.7
93.8
|
L
 8.8%
H
27.7
121.1
|
L
 88.1%
H
15.5
121.1
|
L
H
15.5
121.1
|
| PepGen Inc |
|
354.7
|
5.2
|
L
 -7.9%
H
5.1
5.6
|
L
 -24.6%
H
5.1
7.5
|
L
 -8.8%
H
5.1
7.8
|
L
 13.4%
H
4.1
7.8
|
L
 84.3%
H
0.9
7.8
|
L
 -67.8%
H
0.9
20
|
L
H
0.9
20
|
L
H
0.9
20
|
| Precigen Inc |
|
1,567.4
|
4.4
|
L
 6.2%
H
4.1
4.5
|
L
 -2.6%
H
3.9
5.0
|
L
 20.1%
H
3.6
5.0
|
L
 38.0%
H
3.1
5.2
|
L
 314.0%
H
1.1
5.2
|
L
 120.4%
H
0.7
5.2
|
L
 -47.4%
H
0.7
9.9
|
L
 -79.3%
H
0.7
40.2
|
| Phio Pharma Corp |
|
12.1
|
1.1
|
L
 -5.1%
H
1.1
1.2
|
L
 -2.6%
H
1.1
1.2
|
L
H
1
1.2
|
L
 -48.6%
H
1
4.2
|
L
 -83.0%
H
1.0
4.8
|
L
 -98.1%
H
0.6
110.4
|
L
 -99.6%
H
0.6
470.9
|
L
 -100.0%
H
0.6
207900
|
| Pliant Therapeutics Inc |
|
80.5
|
1.3
|
L
 1.6%
H
1.3
1.3
|
L
 2.3%
H
1.3
1.4
|
L
 6.5%
H
1.2
1.4
|
L
 -12.1%
H
1.2
2.0
|
L
 -88.9%
H
1.1
12.8
|
L
 -94.4%
H
1.1
36.6
|
L
 -95.3%
H
1.1
43.9
|
L
H
1.1
43.9
|
| Pluri Inc |
|
28.4
|
3.1
|
L
 -5.3%
H
3.0
3.3
|
L
 5.1%
H
2.9
3.3
|
L
 -0.3%
H
2.8
3.7
|
L
 -31.5%
H
2.8
4.9
|
L
 -27.4%
H
2.8
7.1
|
L
 -66.6%
H
0.7
10.8
|
L
 -95.3%
H
0.7
73.4
|
L
 -95.5%
H
0.7
169.6
|
| Prelude Therapeutics Inc |
|
141.4
|
2.3
|
L
 0.5%
H
2.1
2.3
|
L
 -12.1%
H
2.1
3.0
|
L
 31.6%
H
1.7
3
|
L
 80%
H
1.2
4.2
|
L
 118.5%
H
0.6
4.2
|
L
 -62.6%
H
0.6
8.6
|
L
 -96.8%
H
0.6
95.4
|
L
H
0.6
95.4
|
| Prime Medicine Inc |
|
794.2
|
4.4
|
L
 5.8%
H
4.1
4.6
|
L
 18.9%
H
3.8
4.6
|
L
 7.3%
H
3.3
4.6
|
L
 -22.1%
H
3.2
6.7
|
L
 58.8%
H
1.1
6.9
|
L
 -72.4%
H
1.1
21.5
|
L
H
1.1
21.7
|
L
H
1.1
21.7
|
| ProKidney Corp Ordinary |
|
322.7
|
2.3
|
L
 -0.4%
H
2.3
2.4
|
L
 1.3%
H
2.2
2.5
|
L
 3.2%
H
2.1
2.6
|
L
 -23.8%
H
2.0
3.5
|
L
 38.2%
H
0.5
7.1
|
L
 -73.0%
H
0.5
14.2
|
L
H
0.5
14.2
|
L
H
0.5
14.2
|
| Prothena Corporation plc |
|
492.5
|
9.2
|
L
 1.9%
H
8.8
9.3
|
L
 2.0%
H
8.7
9.5
|
L
 -11.7%
H
8.7
10.5
|
L
 -11.6%
H
8.7
11.7
|
L
 -30.3%
H
4.3
16.7
|
L
 -83.9%
H
4.3
79.7
|
L
 -32.8%
H
4.3
79.8
|
L
 -80.2%
H
4.3
79.8
|
| AlphaTON Cap Corp |
|
8.3
|
0.9
|
L
 -30%
H
0.9
1.1
|
L
 -9%
H
0.9
3.3
|
L
 -31.1%
H
0.6
3.3
|
L
 -86.1%
H
0.6
7.4
|
L
 -78.7%
H
0.6
15.8
|
L
 -99.2%
H
0.6
116.6
|
L
 -99.8%
H
0.6
899.5
|
L
 -99.5%
H
0.2
1310
|
| Protagonist Therapeutics Inc |
|
5,302.0
|
84.8
|
L
 4.2%
H
80.5
85.1
|
L
 3.1%
H
78.8
85.1
|
L
 -11.1%
H
78.8
96.5
|
L
 7.1%
H
73.1
96.5
|
L
 128.4%
H
33.7
96.5
|
L
 596.9%
H
11.2
96.5
|
L
 297.6%
H
6.9
96.5
|
L
H
4.5
96.5
|
| PureTech Health Plc ADR |
|
447.1
|
18.5
|
L
 2.2%
H
18.4
18.8
|
L
 10.2%
H
16.7
18.8
|
L
 9.4%
H
16.5
18.8
|
L
 4.9%
H
15.5
18.9
|
L
 5.8%
H
13.3
20
|
L
 -37.2%
H
13.3
38.5
|
L
 -66.4%
H
13.3
65.9
|
L
H
13.3
65.9
|
| Quince Therapeutics Inc |
|
167.0
|
3
|
L
 -0.3%
H
2.9
3.1
|
L
 7.9%
H
2.6
3.2
|
L
 -28.9%
H
2.6
4.3
|
L
 53.1%
H
1.4
4.6
|
L
 73.4%
H
0.7
4.6
|
L
 289.6%
H
0.5
4.6
|
L
 -89.8%
H
0.5
122.0
|
L
H
0.5
122.0
|
| uniQure NV |
|
1,386.0
|
22.3
|
L
 3.5%
H
21.2
22.9
|
L
 -0.3%
H
21.2
28.8
|
L
 14.0%
H
19.3
28.8
|
L
 -64.1%
H
19.3
71.5
|
L
 61.4%
H
7.8
71.5
|
L
 -3.6%
H
3.7
71.5
|
L
 -41.5%
H
3.7
71.5
|
L
 51.8%
H
3.7
82.5
|
| Rain Oncology Inc |
|
128.8
|
3.5
|
L
H
3.5
3.5
|
L
 -7.1%
H
3.5
4.1
|
L
 -42.8%
H
3.5
8.5
|
L
 -26.3%
H
3.5
8.5
|
L
 192.6%
H
1.4
9.2
|
L
 -67.1%
H
0.8
11.3
|
L
H
0.8
23.9
|
L
H
0.8
23.9
|
| Rani Therapeutics Holdings Inc |
|
135.6
|
1.4
|
L
 -2.1%
H
1.4
1.4
|
L
 0.7%
H
1.4
1.5
|
L
 3.7%
H
1.3
1.5
|
L
 195.7%
H
0.5
3.9
|
L
 6.9%
H
0.4
3.9
|
L
 -78.7%
H
0.4
8.8
|
L
 -99.3%
H
0.4
36.3
|
L
H
0.4
224.5
|
| Rocket Pharmaceuticals Inc |
|
417.7
|
3.9
|
L
 1.6%
H
3.8
3.9
|
L
 9.0%
H
3.5
4.1
|
L
 13.9%
H
3.2
4.1
|
L
 11.2%
H
2.8
4.5
|
L
 -64.0%
H
2.2
11.5
|
L
 -82.7%
H
2.2
32.5
|
L
 -93.0%
H
2.2
67.5
|
L
 -87.8%
H
2.2
67.5
|
| Replimune Grp Inc |
|
618.1
|
7.9
|
L
 -2.0%
H
7.8
8.2
|
L
 -6.8%
H
7.8
9.4
|
L
 -22.6%
H
7.8
10.3
|
L
 72.8%
H
4.3
11.3
|
L
 -27.6%
H
2.7
14.8
|
L
 -71.9%
H
2.7
29.5
|
L
 -81.8%
H
2.7
46.6
|
L
H
2.7
54.9
|
| Revelation Biosciences Inc |
|
5.3
|
0.9
|
L
H
0.9
0.9
|
L
 -2.2%
H
0.9
0.9
|
L
 -14.3%
H
0.8
1.1
|
L
 -32.8%
H
0.8
1.4
|
L
 -96.3%
H
0.7
25.5
|
L
 -100.0%
H
0.7
16405.2
|
L
 -100.0%
H
0.7
569016
|
L
H
0.7
569016
|
| Relay Therapeutics Inc |
|
1,421.2
|
8.2
|
L
 3.3%
H
7.9
8.4
|
L
 0.4%
H
7.6
8.7
|
L
 2.1%
H
7.6
9.0
|
L
 30.8%
H
5.9
9.0
|
L
 71.6%
H
1.8
9.0
|
L
 -60.5%
H
1.8
23.2
|
L
 -80.5%
H
1.8
64.4
|
L
H
1.8
64.4
|
| Avidity Biosciences Inc |
|
10,924.0
|
72.5
|
L
 0.1%
H
72.4
72.6
|
L
 0.4%
H
72.2
72.6
|
L
 0.9%
H
71.7
72.6
|
L
 48.1%
H
46.1
72.6
|
L
 155.2%
H
21.5
72.6
|
L
 220.1%
H
4.8
72.6
|
L
 171.2%
H
4.8
72.6
|
L
H
4.8
72.6
|
| TransCode Therapeutics Inc |
|
8.4
|
9.2
|
L
 7.5%
H
7.9
9.3
|
L
 24.7%
H
7.1
9.3
|
L
 -3.5%
H
6.1
9.6
|
L
 -32.1%
H
6.1
15.9
|
L
 -89.7%
H
6.1
468.4
|
L
 -100.0%
H
6.1
790944
|
L
H
6.1
5174400
|
L
H
6.1
5174400
|
| Recursion Pharma Inc (Class A) |
|
2,461.8
|
4.7
|
L
 0.9%
H
4.6
4.8
|
L
 4.0%
H
4.5
5
|
L
 9.2%
H
4.1
5.0
|
L
 -14.5%
H
3.8
7.2
|
L
 -29.8%
H
3.8
12.4
|
L
 -45.6%
H
3.8
16.7
|
L
H
3.8
42.8
|
L
H
3.8
42.8
|
| Rhythm Pharma Inc |
|
7,457.8
|
111.8
|
L
 3.7%
H
106.1
112.1
|
L
 12.4%
H
96.2
112.1
|
L
 -1.6%
H
96.2
116.3
|
L
 10.9%
H
95.3
122.2
|
L
 103.6%
H
45.9
122.2
|
L
 257.6%
H
15.5
122.2
|
L
 242.6%
H
3.0
122.2
|
L
H
3.0
122.2
|
| SAB Biotherapeutics Inc |
|
188.5
|
4.0
|
L
 0.5%
H
3.8
4
|
L
 9.4%
H
3.4
4.2
|
L
 3.9%
H
3.4
4.2
|
L
 71.4%
H
2.1
4.2
|
L
 8.2%
H
1
6.6
|
L
 435.1%
H
0.4
6.6
|
L
H
0.4
12.9
|
L
H
0.4
12.9
|
| Sana biotech Inc |
|
1,270.6
|
4.8
|
L
 1.5%
H
4.6
4.9
|
L
 9.4%
H
4.4
4.9
|
L
 -7.2%
H
3.9
5.4
|
L
 9.9%
H
3.2
6.6
|
L
 37.9%
H
1.3
6.6
|
L
 0.8%
H
1.3
12
|
L
H
1.3
44.6
|
L
H
1.3
44.6
|
| Cassava Sciences Inc |
|
103.9
|
2.2
|
L
 4.9%
H
2.1
2.2
|
L
 1.4%
H
2.0
2.3
|
L
 -26.6%
H
2.0
3.0
|
L
 -47.6%
H
2.0
5.0
|
L
 -21.3%
H
1.2
5.0
|
L
 -93.7%
H
1.2
42.2
|
L
 -81.2%
H
1.2
146.2
|
L
 -81.5%
H
0.8
146.2
|
| Seer Inc (Class A) |
|
106.3
|
1.9
|
L
 -1.1%
H
1.9
1.9
|
L
 3.3%
H
1.8
2.0
|
L
 7.4%
H
1.8
2.0
|
L
 -14.5%
H
1.8
2.4
|
L
 -18.5%
H
1.6
2.4
|
L
 -63.7%
H
1.5
6.2
|
L
 -97.4%
H
1.5
86.6
|
L
H
1.5
86.6
|
| Selecta Biosciences Inc |
|
1,186.2
|
7.7
|
L
 5.4%
H
7.0
7.8
|
L
 8.8%
H
7.0
8.3
|
L
 -10.1%
H
6.4
9.2
|
L
 -19.4%
H
6.0
10.2
|
L
 -25.3%
H
6.0
15.6
|
L
 -25.3%
H
6.0
15.6
|
L
 -25.3%
H
6.0
15.6
|
L
 -25.3%
H
6.0
15.6
|
| Sangamo Therapeutics Inc |
|
148.1
|
0.4
|
L
 -2.2%
H
0.4
0.5
|
L
H
0.4
0.5
|
L
 -2.2%
H
0.4
0.5
|
L
 -35.3%
H
0.4
0.7
|
L
 -59.3%
H
0.4
1.4
|
L
 -87.9%
H
0.3
3.7
|
L
 -97.2%
H
0.3
16.8
|
L
 -92.8%
H
0.3
27.5
|
| Solid Biosciences Inc |
|
457.3
|
5.9
|
L
 13.8%
H
5.2
5.9
|
L
 6.9%
H
4.9
5.9
|
L
H
4.9
6.2
|
L
 -2.3%
H
3.8
6.5
|
L
 77.3%
H
2.4
7.4
|
L
 -13.0%
H
1.8
15.1
|
L
 -94.1%
H
1.8
173.7
|
L
H
1.8
822.6
|
| Summit Therapeutics Inc |
|
13,065.0
|
17.6
|
L
 4.4%
H
16.8
17.7
|
L
 -6.0%
H
16.3
20.2
|
L
 -0.1%
H
16.3
20.2
|
L
 -23.5%
H
15.6
23.6
|
L
 -3.5%
H
15.6
36.9
|
L
 265.6%
H
1.3
36.9
|
L
 232.4%
H
0.7
36.9
|
L
 90.3%
H
0.7
36.9
|
| Syndax Pharma Inc |
|
1,809.6
|
20.8
|
L
 1.7%
H
20.3
21.1
|
L
 2.4%
H
19.6
22.4
|
L
 2.2%
H
19.6
22.7
|
L
 37.0%
H
13.0
22.7
|
L
 62.7%
H
8.6
22.7
|
L
 -20.9%
H
8.6
29.9
|
L
 -11.1%
H
8.6
29.9
|
L
H
3.4
29.9
|
| Sensei Biotherapeutics Inc |
|
14.7
|
11.7
|
L
 -0.7%
H
11.4
11.9
|
L
 7.4%
H
10.2
11.9
|
L
 36.6%
H
7.8
11.9
|
L
 -0.9%
H
7.5
18.4
|
L
 10.2%
H
5
18.4
|
L
 -62.8%
H
5
38.8
|
L
H
5
530
|
L
H
5
530
|
| Senti Biosciences Inc |
|
27.9
|
1.1
|
L
H
1.0
1.1
|
L
 -3.6%
H
1.0
1.2
|
L
 -19.1%
H
1.0
1.3
|
L
 -36.9%
H
1.0
2.9
|
L
 -72.0%
H
1.0
5.1
|
L
 -94.4%
H
1.0
21.1
|
L
H
0.7
87.7
|
L
H
0.7
87.7
|
| Spruce Biosciences Inc |
|
80.9
|
75.6
|
L
 -7.3%
H
75.4
84.5
|
L
 -6.2%
H
72.9
84.5
|
L
 -9.4%
H
71.3
91.1
|
L
 -52.5%
H
71.3
188.3
|
L
 183.9%
H
4.3
240
|
L
 -63.5%
H
4.3
446.3
|
L
 -95.6%
H
4.3
2136.8
|
L
H
4.3
2670
|
| Spero Therapeutics Inc |
|
140.8
|
2.5
|
L
 2.0%
H
2.4
2.5
|
L
 -0.4%
H
2.4
2.7
|
L
 7.8%
H
2.3
2.7
|
L
 9.2%
H
2.2
2.8
|
L
 163.2%
H
0.5
3.2
|
L
 25%
H
0.5
3.2
|
L
 -84.5%
H
0.5
22.2
|
L
H
0.5
23.6
|
| Scholar Rock Holding Corp |
|
4,705.6
|
46.1
|
L
 5.4%
H
43.2
46.7
|
L
 11.7%
H
40.6
46.7
|
L
 -1.6%
H
40.6
46.8
|
L
 34.6%
H
27.1
48.3
|
L
 8.3%
H
22.7
48.3
|
L
 283.1%
H
5.6
48.3
|
L
 -13.8%
H
4.3
70
|
L
H
4.3
70
|
| Surrozen Inc |
|
170.0
|
19.8
|
L
 -4.0%
H
19.8
20.8
|
L
 0.8%
H
16.8
21.0
|
L
 -19.4%
H
16.8
24.8
|
L
 43.5%
H
11.4
24.9
|
L
 75.2%
H
5.9
24.9
|
L
 3098.4%
H
0.3
24.9
|
L
H
0.3
24.9
|
L
H
0.3
24.9
|
| Stoke Therapeutics Inc |
|
1,736.9
|
30.4
|
L
 -0.6%
H
30.1
30.9
|
L
 -13.7%
H
25.2
37.3
|
L
 -6.1%
H
25.2
37.3
|
L
 0.2%
H
20.3
38.7
|
L
 240.9%
H
5.4
38.7
|
L
 211.9%
H
3.4
38.7
|
L
 -47.7%
H
3.4
71.6
|
L
H
3.4
71.6
|
| Shattuck Labs Inc |
|
298.7
|
4.7
|
L
 4.7%
H
4.4
4.8
|
L
 18.6%
H
4.0
4.9
|
L
 52.3%
H
2.8
4.9
|
L
 156.5%
H
1.7
4.9
|
L
 296.6%
H
0.7
4.9
|
L
 62.2%
H
0.7
11.8
|
L
 -90.0%
H
0.7
59.6
|
L
H
0.7
60.5
|
| 60 Degrees Pharma Inc |
|
2.0
|
0.5
|
L
 -9.4%
H
0.3
0.6
|
L
 -7.7%
H
0.3
0.6
|
L
 -43.5%
H
0.3
0.9
|
L
 -70.2%
H
0.3
1.8
|
L
 -89.6%
H
0.3
6
|
L
H
0.3
519
|
L
H
0.3
519
|
L
H
0.3
519
|
| Synlogic Inc |
|
13.2
|
1.1
|
L
 0.9%
H
1.1
1.2
|
L
 -5.0%
H
1.1
1.2
|
L
 1.8%
H
1.1
1.3
|
L
 -27.1%
H
1.0
1.9
|
L
 -20.4%
H
0.9
2.0
|
L
 -92.8%
H
0.9
16.3
|
L
 -97.6%
H
0.9
76.7
|
L
 -99.8%
H
0.9
670.9
|
| Alaunos Therapeutics Inc |
|
6.0
|
2.7
|
L
 2.3%
H
2.6
2.8
|
L
 -16.3%
H
2.6
4.0
|
L
 -37.1%
H
2.6
4.5
|
L
 -17.8%
H
2.3
4.5
|
L
 54.0%
H
1.3
6.2
|
L
 235%
H
0.0
6.2
|
L
 -11.8%
H
0.0
6.2
|
L
 -52.7%
H
0.0
9.7
|
| Tscan Therapeutics Inc |
|
67.5
|
1.2
|
L
 1.7%
H
1.1
1.2
|
L
 4.4%
H
1.1
1.3
|
L
 17.8%
H
0.9
1.3
|
L
 -45.9%
H
0.9
2.6
|
L
 -56.3%
H
0.9
2.9
|
L
 -45.9%
H
0.9
9.7
|
L
H
0.9
14.7
|
L
H
0.9
14.7
|
| Bio-Techne |
|
10,621.8
|
68.2
|
L
 2.7%
H
65.8
68.4
|
L
 4.4%
H
63.4
69
|
L
 16.5%
H
56.6
69
|
L
 14.3%
H
54.2
69
|
L
 -10.8%
H
46.0
79.3
|
L
 -15.7%
H
46.0
89.9
|
L
 -17.5%
H
46.0
136.0
|
L
 230.9%
H
20.0
136.0
|
| Terns Pharma Inc |
|
4,112.5
|
37.8
|
L
 9.8%
H
34.0
38.4
|
L
 -1.3%
H
33.4
40.8
|
L
 -16.0%
H
33.4
45.2
|
L
 361.1%
H
7.0
48.3
|
L
 687.7%
H
1.9
48.3
|
L
 318.3%
H
1.9
48.3
|
L
H
1.5
48.3
|
L
H
1.5
48.3
|
| Instil Bio Inc |
|
48.6
|
7.2
|
L
 -0.6%
H
7
7.3
|
L
 7.5%
H
6.7
7.4
|
L
 -34.0%
H
5.7
12.9
|
L
 -64.9%
H
5.7
21.6
|
L
 -62.4%
H
5.7
42.8
|
L
 817.9%
H
0.3
92
|
L
H
0.3
92
|
L
H
0.3
92
|
| Tango Therapeutics Inc |
|
1,628.2
|
12.1
|
L
 15.8%
H
10.4
12.4
|
L
 25.0%
H
9.7
12.4
|
L
 29.3%
H
8.3
12.4
|
L
 42.7%
H
6.7
12.4
|
L
 322.7%
H
1.0
12.4
|
L
 50%
H
1.0
13.0
|
L
H
1.0
18.8
|
L
H
1.0
18.8
|
| Entrada Therapeutics Inc |
|
395.2
|
10.3
|
L
 -1.2%
H
10.0
10.5
|
L
 2.6%
H
9.3
10.9
|
L
 -6.7%
H
9.3
11.6
|
L
 78.0%
H
5.6
11.6
|
L
 -22.7%
H
4.9
14.3
|
L
 -24.6%
H
4.9
21.8
|
L
H
4.9
36.9
|
L
H
4.9
36.9
|
| Trevi Therapeutics Inc |
|
1,493.9
|
11.7
|
L
 3.2%
H
11.1
11.7
|
L
 6.1%
H
10.9
11.8
|
L
 -8.8%
H
10.6
13.2
|
L
 20.0%
H
9.3
14.4
|
L
 192.0%
H
3.5
14.4
|
L
 344.7%
H
1.0
14.4
|
L
 288.3%
H
0.5
14.4
|
L
H
0.5
14.4
|
| Taysha Gene Therapies Inc |
|
1,402.5
|
5.1
|
L
 4.5%
H
4.8
5.2
|
L
 -2.7%
H
4.6
5.7
|
L
 -11.6%
H
4.6
6.0
|
L
 1.4%
H
3.7
6.0
|
L
 206.6%
H
1.1
6.0
|
L
 122.6%
H
0.5
6.0
|
L
 -81.7%
H
0.5
33.4
|
L
H
0.5
33.4
|
| Twist Bioscience Corp |
|
2,414.2
|
39.4
|
L
 -2.0%
H
38.7
40.9
|
L
 6.9%
H
34.6
41.3
|
L
 27.4%
H
30.2
41.3
|
L
 30.7%
H
23.3
41.3
|
L
 -9.6%
H
23.3
55.3
|
L
 51.8%
H
11.5
60.9
|
L
 -76.6%
H
11.5
214.1
|
L
H
11.5
214.1
|
| 10x Genomics Inc (Class A) |
|
2,627.2
|
20.8
|
L
 1.2%
H
20.0
21.0
|
L
 7.5%
H
18.4
21.2
|
L
 34.3%
H
15.2
21.2
|
L
 79.0%
H
11.2
21.2
|
L
 32.2%
H
6.8
21.2
|
L
 -52.0%
H
6.8
63.6
|
L
 -88.2%
H
6.8
209.0
|
L
H
6.8
209.0
|
| UroGen Pharma Ltd |
|
886.6
|
18.9
|
L
 -4.5%
H
18.1
20.0
|
L
 -13.5%
H
18.1
24.1
|
L
 -13.1%
H
18.1
24.7
|
L
 13.0%
H
16.3
30
|
L
 86.1%
H
3.4
30
|
L
 121.3%
H
3.4
30
|
L
 -6.7%
H
3.4
30
|
L
H
3.4
69.6
|
| Vera Therapeutics Inc (Class A) |
|
3,458.5
|
48.7
|
L
 -0.8%
H
47.2
49.8
|
L
 4.7%
H
45.0
50.8
|
L
 -2.2%
H
45.0
56.1
|
L
 59.8%
H
23.1
56.1
|
L
 40.1%
H
18.5
56.1
|
L
 622.8%
H
6.0
56.1
|
L
H
5.2
56.1
|
L
H
5.2
56.1
|
| Vir biotech Inc |
|
944.7
|
6.8
|
L
 7.6%
H
6.3
6.8
|
L
 13.9%
H
5.7
6.8
|
L
 1.5%
H
5.6
7.0
|
L
 15.9%
H
4.8
7.1
|
L
 -35.5%
H
4.2
11.4
|
L
 -74.4%
H
4.2
31.6
|
L
 -80.9%
H
4.2
141.0
|
L
H
4.2
141.0
|
| Vor Biopharma Inc |
|
321.9
|
14.7
|
L
 8.9%
H
13
15.0
|
L
 25.9%
H
11.7
15.0
|
L
 17.4%
H
10.3
16.8
|
L
 -54.5%
H
6.5
33.4
|
L
 972.3%
H
0.1
50.0
|
L
 150.3%
H
0.1
50.0
|
L
H
0.1
63.6
|
L
H
0.1
63.6
|
| Verastem Inc |
|
515.2
|
6.8
|
L
 -5%
H
6.8
7.3
|
L
 -0.6%
H
6.8
8.9
|
L
 -28.8%
H
6.7
9.9
|
L
 -26.4%
H
6.7
10.8
|
L
 28.1%
H
4.0
11.2
|
L
 -6.2%
H
2.1
15.2
|
L
 -75.9%
H
2.1
59.2
|
L
 -56.8%
H
2.1
124.2
|
| VistaGen Therapeutics Inc |
|
28.0
|
0.7
|
L
 2.9%
H
0.7
0.7
|
L
 -1.4%
H
0.7
0.8
|
L
 -83.3%
H
0.6
4.5
|
L
 -81.8%
H
0.6
5.1
|
L
 -75.8%
H
0.6
5.1
|
L
 -85.2%
H
0.6
24.7
|
L
 -99.0%
H
0.6
106.5
|
L
 -99.7%
H
0.6
298.5
|
| Ventyx Biosciences Inc |
|
995.2
|
13.9
|
L
 0.1%
H
13.8
13.9
|
L
 38.0%
H
13.4
15.3
|
L
 69.4%
H
7.1
25
|
L
 273.9%
H
3.4
25
|
L
 611.3%
H
0.8
25
|
L
 -60.1%
H
0.8
47.3
|
L
H
0.8
47.3
|
L
H
0.8
47.3
|
| Voyager Therapeutics Inc |
|
229.1
|
4.1
|
L
 2.5%
H
4.0
4.2
|
L
 2.5%
H
3.8
4.2
|
L
 -6.2%
H
3.8
4.6
|
L
 -15.8%
H
3.7
5.6
|
L
 -22.0%
H
2.6
6.0
|
L
 -61.8%
H
2.6
14.3
|
L
 -51.9%
H
2.5
14.3
|
L
 -72.1%
H
2.5
31.9
|
| Valneva SE (ADR) |
|
894.8
|
10.3
|
L
 2.8%
H
10.2
10.4
|
L
 5.9%
H
9.6
10.4
|
L
 18.9%
H
8.0
10.4
|
L
 -1.7%
H
8.0
10.6
|
L
 132.4%
H
4.2
12.3
|
L
 -28.4%
H
3.6
17.1
|
L
H
3.6
67.8
|
L
H
3.6
67.8
|
| Wave Life Sciences Ltd |
|
2,725.1
|
14.7
|
L
 3.2%
H
14.0
16.0
|
L
 -3.2%
H
13.5
16.3
|
L
 -11.4%
H
13.5
19.5
|
L
 88.3%
H
6.5
21.7
|
L
 30.2%
H
5.3
21.7
|
L
 168.7%
H
3.2
21.7
|
L
 65.6%
H
1.2
21.7
|
L
 10.7%
H
1.2
56
|
| XBiotech Inc |
|
80.2
|
2.6
|
L
 2.7%
H
2.5
2.6
|
L
 4.0%
H
2.5
2.7
|
L
 9.6%
H
2.3
2.7
|
L
 2.7%
H
2.1
3.4
|
L
 -31.7%
H
2.1
4
|
L
 -43.6%
H
2.1
10.0
|
L
 -84.4%
H
2.1
20.8
|
L
 -66.5%
H
2.1
26.4
|
| Exicure Inc |
|
38.4
|
6.0
|
L
 1.5%
H
6.0
6.2
|
L
 2.2%
H
5.7
6.3
|
L
 -5.2%
H
5.3
6.6
|
L
 17.1%
H
3.5
9.5
|
L
 -23.8%
H
3.1
15.9
|
L
 -8.1%
H
0.3
36
|
L
 -98.3%
H
0.3
424.5
|
L
H
0.3
975
|
| Xeris Biopharma Holdings Inc |
|
1,251.1
|
7.5
|
L
 -2.2%
H
7.5
7.7
|
L
 8.3%
H
7.0
8.4
|
L
 5.2%
H
6.9
8.4
|
L
 -5.2%
H
6.5
10.1
|
L
 129.9%
H
3.1
10.1
|
L
 489.1%
H
1.1
10.1
|
L
 31.1%
H
1.0
10.1
|
L
H
1.0
28.0
|
| X4 Pharma Inc |
|
336.6
|
3.9
|
L
 -0.5%
H
3.8
3.9
|
L
 -2.8%
H
3.7
4.2
|
L
 -1.5%
H
3.5
4.6
|
L
 25.8%
H
2.8
4.6
|
L
 587.5%
H
0.2
6.6
|
L
 218.2%
H
0.2
6.6
|
L
 -51.8%
H
0.2
10.7
|
L
H
0.2
172.2
|
| Xencor Inc |
|
1,023.3
|
14.3
|
L
 2.8%
H
13.7
14.7
|
L
 1.9%
H
13.7
15.4
|
L
 -13.3%
H
13.7
17.2
|
L
 2.7%
H
11.2
18.7
|
L
 -29.3%
H
6.9
21
|
L
 -49.4%
H
6.9
38.2
|
L
 -70.1%
H
6.9
58.3
|
L
 22.0%
H
6.9
58.3
|
| 22nd Century Grp Inc |
|
6.4
|
0.8
|
L
 2.4%
H
0.8
0.9
|
L
 -8.7%
H
0.8
1.0
|
L
 -20%
H
0.8
1.1
|
L
 -47.5%
H
0.8
1.8
|
L
 -99.4%
H
0.8
225.4
|
L
 -100.0%
H
0.8
942678
|
L
 -100.0%
H
0.8
4523364
|
L
 -100.0%
H
0.8
4523364
|
| Zentalis Pharma Inc |
|
251.4
|
3.5
|
L
H
3.3
3.5
|
L
 95.5%
H
1.7
4.0
|
L
 148.6%
H
1.3
4.0
|
L
 114.8%
H
1.2
4.0
|
L
 35.9%
H
1.0
4.0
|
L
 -86.0%
H
1.0
31.5
|
L
 -93.1%
H
1.0
87.2
|
L
H
1.0
87.2
|
| Zura Bio Ltd (Class A) |
|
351.8
|
5.4
|
L
 4.8%
H
5.0
5.5
|
L
 12.0%
H
4.8
5.6
|
L
 34.6%
H
3.9
5.8
|
L
 40.2%
H
3.2
5.8
|
L
 171.9%
H
1.0
5.8
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
L
H
1.0
37.6
|
| Zai Lab Ltd (ADR) |
|
2,158.1
|
19.5
|
L
 4.1%
H
19.4
19.8
|
L
 7.0%
H
18.0
19.8
|
L
 9.6%
H
16.8
19.8
|
L
 -37.6%
H
16.8
30.2
|
L
 -22.7%
H
16.8
44.3
|
L
 -59.1%
H
13.5
47
|
L
 -87.3%
H
13.5
193.5
|
L
H
13.5
193.5
|
| Apogee Therapeutics Inc |
|
5,591.3
|
81.8
|
L
 3.6%
H
78.1
84.6
|
L
 4.6%
H
75.0
84.6
|
L
 6.2%
H
72.6
84.6
|
L
 51.6%
H
51.8
84.6
|
L
 100.1%
H
26.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
L
H
14.2
84.6
|
| Intensity Therapeutics Inc |
|
25.8
|
0.4
|
L
 2.4%
H
0.4
0.4
|
L
 7.5%
H
0.4
0.4
|
L
 -8.5%
H
0.4
0.5
|
L
 43.3%
H
0.2
1.7
|
L
 -81.1%
H
0.2
3.2
|
L
 -89.3%
H
0.2
11.4
|
L
 -89.3%
H
0.2
11.4
|
L
 -89.3%
H
0.2
11.4
|
| Renovaro Biosciences Inc |
|
21.6
|
0.9
|
L
 -5.2%
H
0.9
1.0
|
L
H
0.9
1
|
L
 -14.0%
H
0.9
1.1
|
L
 -35.2%
H
0.8
1.7
|
L
 -89.8%
H
0.8
14
|
L
H
0.8
52.5
|
L
H
0.8
52.5
|
L
H
0.8
52.5
|
| Elutia Inc (Class A) |
|
35.9
|
0.8
|
L
 -4.6%
H
0.8
0.9
|
L
 33.3%
H
0.6
0.9
|
L
 20%
H
0.5
0.9
|
L
 -6.7%
H
0.5
1.0
|
L
 -73.2%
H
0.5
3.5
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
L
H
0.5
5.2
|
| Tharimmune Inc |
|
110.3
|
3.0
|
L
 2.1%
H
2.8
3
|
L
 -4.5%
H
2.8
3.1
|
L
 23.4%
H
2.2
3.6
|
L
 1.0%
H
2.2
6.9
|
L
 52.9%
H
1.0
9.1
|
L
 -98.1%
H
0.3
993.8
|
L
H
0.3
1590
|
L
H
0.3
1590
|
| Gyre Therapeutics Inc |
|
741.8
|
7.7
|
L
 -1.2%
H
7.7
7.9
|
L
 10.5%
H
7.1
7.9
|
L
 0.1%
H
6.8
8.1
|
L
 -8.2%
H
6.8
9.4
|
L
 -22.9%
H
6.1
13.7
|
L
 2.7%
H
5.6
130.5
|
L
 2.7%
H
5.6
130.5
|
L
 2.7%
H
5.6
130.5
|
| Lexeo Therapeutics Inc |
|
558.4
|
7.7
|
L
 3.0%
H
7.4
7.8
|
L
 -19.6%
H
6.9
10.8
|
L
 -21.7%
H
6.9
11.0
|
L
 -6.7%
H
6.9
11.0
|
L
 20.7%
H
1.5
11.0
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
L
H
1.5
22.3
|
| Korro Bio Inc |
|
84.8
|
9.0
|
L
 0.2%
H
8.8
9.1
|
L
 9.1%
H
8.1
9.6
|
L
 9.5%
H
7.6
9.6
|
L
 -80.3%
H
5.2
55.9
|
L
 -76.4%
H
5.2
55.9
|
L
H
5.2
98
|
L
H
5.2
98
|
L
H
5.2
98
|
| Cartesian Therapeutics Inc |
|
198.4
|
7.6
|
L
 -0.4%
H
7.3
7.7
|
L
 8.4%
H
7.0
8.3
|
L
 -10.5%
H
6.4
9.2
|
L
 -19.7%
H
6.0
10.2
|
L
 -58.4%
H
6.0
20.1
|
L
 -99.5%
H
6.0
1791
|
L
 -99.7%
H
6.0
5130
|
L
H
6.0
25199.6
|
| Elevai Labs Inc |
|
4.3
|
3.6
|
L
 -10.5%
H
3.5
3.9
|
L
 -35.9%
H
3.5
7.1
|
L
 -6.5%
H
1.3
9.6
|
L
 -30.9%
H
1.3
11.1
|
L
 -93.0%
H
1.3
99.7
|
L
H
1.3
20796.6
|
L
H
1.3
20796.6
|
L
H
1.3
20796.6
|
| Spyre Therapeutics Inc |
|
2,588.5
|
33.4
|
L
 5.8%
H
31.5
34.2
|
L
 10.0%
H
29.6
34.2
|
L
 -0.8%
H
28
35.0
|
L
 76.3%
H
18.7
35.3
|
L
 54.8%
H
10.9
35.3
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
L
H
8.8
48.0
|
| Neurogene Inc |
|
286.1
|
18.5
|
L
 9.0%
H
16.9
18.6
|
L
 0.9%
H
16.5
19.8
|
L
 -11.7%
H
16.5
23.0
|
L
 -41.6%
H
16.5
37.3
|
L
 -1.8%
H
6.9
37.3
|
L
 30.3%
H
6.9
74.5
|
L
 30.3%
H
6.9
74.5
|
L
 30.3%
H
6.9
74.5
|
| Cg Oncology Inc |
|
4,430.2
|
54.9
|
L
 4.5%
H
51.6
55.9
|
L
 36.0%
H
40.2
57.4
|
L
 34.2%
H
37.0
57.4
|
L
 27.8%
H
35.8
57.4
|
L
 91.5%
H
14.8
57.4
|
L
H
14.8
57.4
|
L
H
14.8
57.4
|
L
H
14.8
57.4
|
| FibroBiologics Inc |
|
23.3
|
0.4
|
L
 2.9%
H
0.3
0.4
|
L
 34.6%
H
0.3
0.4
|
L
 -10.3%
H
0.2
0.4
|
L
 -20.5%
H
0.2
0.5
|
L
 -82.5%
H
0.2
2.1
|
L
H
0.2
55
|
L
H
0.2
55
|
L
H
0.2
55
|
| Kyverna Therapeutics Inc |
|
537.7
|
9.0
|
L
 4.2%
H
8.6
9.8
|
L
 13.6%
H
7.8
9.8
|
L
 2.7%
H
6.6
13.7
|
L
 30.2%
H
6.2
13.7
|
L
 174.2%
H
1.8
13.7
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
L
H
1.8
35.1
|
| Metagenomi Inc |
|
65.3
|
1.7
|
L
 1.2%
H
1.7
1.8
|
L
H
1.7
1.9
|
L
 5.5%
H
1.6
1.9
|
L
 -39.0%
H
1.5
4.0
|
L
 -40.2%
H
1.2
4
|
L
H
1.2
15
|
L
H
1.2
15
|
L
H
1.2
15
|
| Tevogen Bio Holdings Inc |
|
63.6
|
0.3
|
L
 3.2%
H
0.3
0.3
|
L
 -8.6%
H
0.3
0.4
|
L
 -20%
H
0.3
0.4
|
L
 -55.6%
H
0.3
0.8
|
L
 -76.8%
H
0.3
1.9
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
L
H
0.3
21.1
|
| NeOnc Tech Holdings Inc |
|
238.0
|
9.9
|
L
 3.7%
H
9.1
9.9
|
L
 11.2%
H
8.8
10.7
|
L
 -2.7%
H
6.4
10.7
|
L
 -12.1%
H
5.6
12
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
L
H
3.2
13.0
|
| LENZ Therapeutics Inc |
|
574.2
|
18.4
|
L
 10.5%
H
16.2
18.5
|
L
 8.9%
H
14.4
18.5
|
L
 1.2%
H
14.4
19.6
|
L
 -52.5%
H
14.4
43.0
|
L
 -20.9%
H
14.4
50.4
|
L
 -26.4%
H
14.4
50.4
|
L
 -26.4%
H
14.4
50.4
|
L
 -26.4%
H
14.4
50.4
|
| Boundless Bio Inc |
|
28.0
|
1.3
|
L
 0.8%
H
1.2
1.3
|
L
 1.6%
H
1.2
1.4
|
L
 6.8%
H
1.1
1.4
|
L
 -3.9%
H
1
1.6
|
L
 -44.4%
H
1
2.8
|
L
H
1
14.7
|
L
H
1
14.7
|
L
H
1
14.7
|
| Contineum Therapeutics Inc (Class A) |
|
400.4
|
11.0
|
L
 0.6%
H
10.7
11.2
|
L
 15.5%
H
8.6
11.2
|
L
 -5.8%
H
8.6
13.0
|
L
 -8.1%
H
8.6
13.5
|
L
 -17.2%
H
3.4
13.6
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
L
H
3.4
21.9
|
| Eupraxia Pharma Inc |
|
430.5
|
8.5
|
L
 2.3%
H
8.1
8.6
|
L
 14.3%
H
7.1
8.7
|
L
 35.6%
H
6.0
8.7
|
L
 40.5%
H
5.3
8.7
|
L
 183.3%
H
2.7
8.7
|
L
H
2.2
8.7
|
L
H
2.2
8.7
|
L
H
2.2
8.7
|
| GridAI Technologies Corp |
|
13.2
|
3.9
|
L
 -0.8%
H
3.9
4
|
L
 -14.8%
H
3.8
5.1
|
L
 33.3%
H
1.9
5.3
|
L
 -30.4%
H
1.9
5.8
|
L
 143.5%
H
1.0
5.8
|
L
 -53.0%
H
0.6
9.5
|
L
 -53.0%
H
0.6
9.5
|
L
 -53.0%
H
0.6
9.5
|
| Artiva Biotherapeutics Inc |
|
115.4
|
4.7
|
L
 2.2%
H
4.5
4.9
|
L
 6.6%
H
4.4
5.2
|
L
 42.4%
H
4
7.3
|
L
 71.5%
H
2.7
7.4
|
L
 -38.6%
H
1.5
7.9
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
L
H
1.5
17.3
|
| MBX Biosciences Inc |
|
1,858.1
|
41.4
|
L
 14.0%
H
36.3
41.8
|
L
 44.2%
H
29.5
41.8
|
L
 38.6%
H
27.0
41.8
|
L
 185.4%
H
12.9
41.8
|
L
 232.1%
H
4.8
41.8
|
L
H
4.8
41.8
|
L
H
4.8
41.8
|
L
H
4.8
41.8
|
| BioAge Labs Inc |
|
844.4
|
23.6
|
L
 13.8%
H
20.4
23.6
|
L
 52.8%
H
13.7
23.6
|
L
 82.8%
H
11.9
23.6
|
L
 328.2%
H
5.0
23.6
|
L
 401.1%
H
2.9
23.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
L
H
2.9
26.6
|
| OnKure Therapeutics Inc (Class A) |
|
43.4
|
3.2
|
L
 1.9%
H
3.2
3.3
|
L
 15.1%
H
2.7
3.4
|
L
 4.2%
H
2.7
3.4
|
L
 11.1%
H
2.5
3.6
|
L
 -55.9%
H
1.7
7.7
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
L
H
1.7
19.4
|
| CAMP4 Therapeutics Corp |
|
-
|
6.0
|
L
 -0.8%
H
5.9
6.1
|
L
 0.3%
H
5.8
6.6
|
L
 -7.4%
H
5.5
7.3
|
L
 66.0%
H
2.9
7.3
|
L
 161.3%
H
1.3
7.3
|
L
 161.3%
H
1.3
7.3
|
L
 161.3%
H
1.3
7.3
|
L
 161.3%
H
1.3
7.3
|
| Upstream Bio Inc |
|
1,730.3
|
32.0
|
L
 -1.8%
H
32.0
33.7
|
L
 23.8%
H
26.1
33.7
|
L
 18.0%
H
25
33.7
|
L
 59.5%
H
19.6
33.7
|
L
 180.1%
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
L
H
5.1
33.7
|
| Medicus Pharma Ltd |
|
35.3
|
1.4
|
L
 -1.4%
H
1.4
1.5
|
L
 -8.9%
H
1.4
1.7
|
L
 -24.3%
H
1.4
2.0
|
L
 -38.4%
H
1.4
2.8
|
L
 -78.8%
H
1.4
8.9
|
L
 -78.8%
H
1.4
8.9
|
L
 -78.8%
H
1.4
8.9
|
L
 -78.8%
H
1.4
8.9
|
| Telix Pharma Ltd (ADR) |
|
2,527.2
|
7.6
|
L
 1.3%
H
7.5
7.6
|
L
 1.2%
H
7.3
7.7
|
L
 -16.4%
H
7.3
8.9
|
L
 -20.9%
H
7.3
11.3
|
L
 -48.2%
H
7.3
30.4
|
L
H
7.3
30.4
|
L
H
7.3
30.4
|
L
H
7.3
30.4
|
| Palvella Therapeutics Inc |
|
1,218.6
|
103.0
|
L
 -0.6%
H
100.3
103.9
|
L
 13.8%
H
90.9
105.7
|
L
 4.4%
H
82.4
114.7
|
L
 35.1%
H
69.0
114.7
|
L
 691.9%
H
12.0
114.7
|
L
 657.0%
H
11.2
114.7
|
L
 657.0%
H
11.2
114.7
|
L
 657.0%
H
11.2
114.7
|
| Sionna Therapeutics Inc |
|
1,782.5
|
39.9
|
L
 8.5%
H
36.1
40.4
|
L
 7.3%
H
34.6
43.3
|
L
 -6.6%
H
34.6
45
|
L
 36.3%
H
28.9
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
L
H
7.3
45
|
| Zenas Biopharma Inc |
|
1,187.9
|
22.1
|
L
 2.6%
H
20.3
22.2
|
L
 45.6%
H
14.7
22.2
|
L
 -45.5%
H
13.5
44.6
|
L
 -16.6%
H
13.5
44.6
|
L
 111.4%
H
8.9
44.6
|
L
 111.4%
H
8.9
44.6
|
L
 111.4%
H
8.9
44.6
|
L
 111.4%
H
8.9
44.6
|
| Propanc Biopharma Inc |
|
5.6
|
0.4
|
L
 -2.3%
H
0.4
0.4
|
L
 -17.7%
H
0.4
0.5
|
L
 -46.8%
H
0.4
0.8
|
L
 -77.1%
H
0.4
1.9
|
L
 -85.4%
H
0.4
9.4
|
L
 -85.4%
H
0.4
9.4
|
L
 -85.4%
H
0.4
9.4
|
L
 -85.4%
H
0.4
9.4
|